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ABSTRACT 
 
 
PREPARATION AND CHARACTERIZATION OF OIL-IN-WATER NANO- 
 
EMULSIONS OF TRIFLUOPERAZINE FOR PARENTERAL DRUG DELIVERY 
 
 
 
 
 
 
 
By 
 
Toluwalope Onadeko 
 
May 2009 
 
 
 
Thesis Supervised by Moji Christianah Adeyeye, PhD 
 
Objectives: 1.) To develop and characterize an optimal formulation of oil-in-water nano-
emulsions of trifluoperazine for parenteral delivery. 2.) To perform short term stability 
testing of the optimal formulation and monitor the potency using high performance 
chromatography (HPLC). 
Materials and Methods: Emulsions containing soybean oil, water, trifluoperazine hcl as 
an amphiphilic drug, phospholipon 90 and Tween 80 as surfactant blend were prepared 
using the Thin-layer hydration method. Z-average, polydispersity index, zeta potential of 
emulsions were determined. A fully randomized 2X2X2X2X2 statistical design was 
developed using JMP software. Optimal formulation was selected based on desirable 
properties of low z-average and polydispersity index, and high zeta potential. Stability of 
optimal formulation was determined using HPLC analysis and based on ICH 
specifications. 
 v 
 
 
Results: Z-average of optimal formulation was 72.9nm with zeta potential value of 25.59 
mV and polydispersity index 0.2. After storage for 3 months, z-average values were 
below 200nm indicating optimal formulation was not physically degraded. Drug content 
analysis showed chemical degradation due to reduction of potency.  
Conclusions: Trifluoperazine nano-emulsions formulations had acceptable values of low 
z-average, low polydispersity index and high zeta potential and were physically stable but 
not chemically stable over 3 months. 
 
 vi 
 
 
DEDICATION 
 
 
 
This work is dedicated to my family. 
 
 vii 
 
 
ACKNOWLEDGEMENTS 
 
 
 
 I would like to express my sincere thanks to my Advisor Dr. Moji Christianah 
Adeyeye for her supervision, advice and encouragement throughout this project and to 
my committee members Dr. Ichikawa (Kobe Gakuin University) and Dr. Meng for their 
assistance and support towards the success of this work. 
 I am grateful to Fred Esseku for his input, patience and assistance with this work. 
My appreciation to Dr. Ana Mofessis (Carnegie Mellon University) for the use of the 
Zeta sizer and Mr Pete Wheeler (Anton Paar) for use of the viscometer. 
My sincere thanks to Dr D’Amico for his assistance with the statistical development.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 iii 
 
 
TABLE OF CONTENTS 
 
Page 
 
ABSTRACT                 iv 
        
DEDICATION                vi 
           
ACKNOWLEDGEMENT                  vii 
 
LIST OF TABLES               xiii 
 
LIST OF FIGURES               xiv 
 
ABBREVATIONS                xvi 
 
1.0 INTRODUCTION                  1 
1.1 Statement of the Problem                  1 
  
1.2 Literature Review                                                                                                           5 
 
1.2.1 Emulsion Technology                  6 
 
1.2.2 Mechanisms of Emulsion Formation                 6 
 
1.2.2.1 Emulsification by Ultrasonication                8
           
1.2.2.2 Emulsification using High Pressure Homogenizers              9
           
1.2.2.3 Phase Inversion Method.                 9
           
1.2.3 Characterization of Emulsions               10
          
1.2.3.1 Particle size determination               10
         
1.2.3.1.1 Photon Correlation Spectroscopy                                    11
            
1.2.3.1.3 Electron Microscopy Techniques                         13
           
1.2.3.1.3.1 Scanning Electron Microscopy                         13
           
1.2.3.1.3.2 Transmission Electron Microscopy (TEM)              13
          
1.2.3.2 Polydispersity Index                14
          
 iv 
 
 
1.2.3.3 Zeta Potential Determination               14
          
1.2.3.4 Viscosity Determination               15
          
1.2.3.4.1 Rolling ball Viscometer               15
          
1.2.3.4.2 Capillary Viscometer               16
         
1.2.3.4.3 Rotational Viscometer               17
         
1.2.4 Emulsion Components and Functionalities             18
          
1.2.4.1 Trifluoperazine                18
          
1.2.4.2 Soybean oil                 20
          
1.2.4.3 Tricaprylin                 21
          
1.2.4.4 Tributyrin                 22
          
1.2.4.5 Ethyl Oleate                 22
          
1.2.4.6 Phosphatidyl choline                23
          
1.2.4.7 Polysorbate 80                24
          
1.2.5 Statistical Experimental Design               25 
 
1.2.6 Stability Studies of Emulsions               26
          
1.2.6.1 Physical Instability                27
          
1.2.6.1.1 Creaming                 27
          
1.2.6.1.2 Flocculation                 27 
                     
1.2.6.1.3 Coalescence                 28  
                    
1.2.6.1.4 Ostwald Ripening                28
         
1.2.6.1.5 Phase Inversion                28
          
1.2.6.3 Chemical Instability                28
          
1.2.6.3 Regulatory Guidelines for Evaluation of Emulsion Stability           29
          
 v 
 
 
2.0 Experimental                 31
          
2.1 Materials                             31
           
2.2 Methodology                 31
          
2.2.1 Preparation of Nano-emulsions               31
          
2.2.1.1 Thin Layer Hydration Method              31
          
2.2.2 Preliminary Emulsion Formulations              32
          
2.2.3 Optimization of Emulsion Components            33          
2.2.4 Z-average analysis, polydispersity index and zeta potential determination         33
          
2.2.5 Viscosity Determination               38
          
2.2.6 Ternary Phase Diagrams               39
         
2.2.7 Statistical Design                39
         
2.2.8 High Performance Liquid Chromatography (HPLC) Analysis and  
         Method Development                            40 
 
2.2.8.1 HPLC Conditions                42
          
2.2.8.2 Preparation of Standard Solutions               42
          
2.2.8.3 Linearity and Range                42
          
2.2.8.4 Precision and Accuracy               43
          
2.2.8.5 Drug Extraction                           43
           
2.2.9 Emulsion Stability                43
          
2.2.9.1 Forced Degradation Study                  43
        
2.2.9.2 Stress Test                 44
          
2.2.9.3 Centrifugation                 44
          
2.2.9.2.2 Freeze/Thaw Cycle                44 
 
2.2.9.3 Accelerated Stability Test               45
          
 vi 
 
 
3.0 Results and Discussion                46
         
3.1 Preliminary Experiment Results               46
         
3.2 Development of Optimal Formulations              52
         
3.3 Phase Diagrams                 57
         
3.4 Viscosity of Emulsions                            60
         
3.5 Statistical Design of Experiments               64
        
3.5.1 Z-average Effects                64
        
3.5.2 Polydispersity Index Effects               64
        
3.5.3 Zeta Potential Effects                64
        
3.5.4 Viscosity effects                65
        
3.5.5 Optimal Emulsions                65
        
3.6 HPLC Method Validation                69
       
3.7 Stability Studies of Optimal Formulations             70
        
3.7.1 Forced Degradation Studies               70
         
3.7.1.1 Z-average and zeta potential                70
        
3.7.1.2 Potency                 71
        
3.7.2 Stress Test of Optimal Formulations              75
        
3.7.2.1 Centrifugation                 75
        
3.7.2.2 Freeze/thaw cycle                75
        
3.7.3 Accelerated Stability Test               77
        
3.7.3.1 Content Analysis of Emulsions 3 and 17             77
        
3.7.3.2 Z-average analysis and Zeta Potential of Emulsions 3 &17 after 3 months          80 
            storage at 40ºC/75% RH                         
  
3.8 Summary                  81 
 vii 
 
 
3.8.1 Emulsion Formulation and Characterization             81
                            
3.8.2 Stability and HPLC Analysis                         82 
4.0 References                            83
                   
5.0 Appendix                  92
       
 
  
 
 
 
 
 
 
 
 
 
 
           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 viii 
 
 
LIST OF TABLES 
 
Page 
 
Table 1. 1 Fatty acid composition of soybean oil 20 
Table 2. 1 List of Materials                34 
Table 2. 2  List of Equipments 35 
Table 2. 3 Formulation Composition: Effect of Surfactant to Oil Ratio 36 
Table 2. 4 Formulation Composition: Effect of Phosphatidyl choline 36 
Table 2. 5 Formulation Composition: Effect of Tween 80 36 
Table 2. 6 Effect of Drug Content 36 
Table 2. 7 Experimental Design Factors 39 
Table 2. 8 2X2X2X2X2 Full Factorial Experimental Design 40 
Table 3. 1 Preliminary Emulsions                                                                                 48 
Table 3. 2 Preliminary Experiments                                                                                  49 
Table 3. 3 Preliminary Experiments: Concentrated Emulsions                                         49 
Table 3. 4 Emulsion Formulations Using 3 Different Sources of Phosphatidyl Choline  49 
Table 3. 5 Emulsions Formulation with increasing Phospholipon 90 H® content            50 
Table 3. 6 Emulsion Composition (Formulation 27)                                                         50 
Table 3. 7 Levels of Emulsion Factors                                                                              61 
Table 3. 8 Statistical Design of Experiment Matrix                                                          62 
Table 3. 9 Parameter Estimates of Size, Polydispersity Index, Zeta Potential and Dynamic 
Viscosity obtained from JMP® by ANOVA                                                              64 
Table 3. 10 Forced Degradation Test                                                                                69 
Table 3. 11 Stress Test                                                                                                       75 
 ix 
 
 
LIST OF FIGURES 
 
Page 
 
Figure 1. 1 Mechanism of Cavitation in Emulsification by Ultrasound 8 
Figure 1. 2 Schematic diagram of a PCS instrument  12 
Figure 1. 3 Structure of Trifluoperazine 18 
Figure 1. 4 Chemical Structure of Tricaprylin  21 
Figure 1. 5 Chemical Structure of Tributyrin 22 
Figure 1. 6 Chemical Structure of Ethyl Oleate 22 
Figure 1. 7 α-phosphatidyl choline 23 
Figure 1. 8 Chemical Structure of  Polyoxeyethylene sorbitan monoester 24 
Figure 2. 1 Branson® Sonicator               33 
Figure 2. 2 Buchi Rotavapor® 33 
Figure 2. 3 Automated Microviscometer (AMVn) 1 
Figure 3.1 Effect different oil phases on Z-average and Polydispersity index of Emulsions
 48 
Figure 3.2 Effect of Soybean oil concentration on Z-average of Emulsions 52 
Figure 3. 3 Effect of Phospholipon 90 on z-average of emulsions at 1:1 Soybean   
Oil:Tween 80 ratio 53 
Figure 3. 4 Effect of Phospholipon 90 on Polydispersity Index of emulsions at 1:1 
Soybean Oil:Tween 80 ratio 53 
Figure 3.5 Effect of Tween 80 on Z. average of Emulsions 54 
Figure 3.6 Effect of Optimization of Drug Content on Z.average Of Nano-emulsions 55 
Figure 3. 7 Effect of Optimization of Drug Content on Z. Potential Of Nano-emulsions 56 
 x 
 
 
Figure 3.8 Ternary Phase diagram of Soybean emulsions showing region of optimal   
formulation 58 
Figure 3.9 Ternary Phase diagram of Soybean emulsions showing experimental design 
formulations 58 
Figure 3.10 Effect of increasing %Phospholipon 90G® on Dynamic Viscosity 60 
Figure 3. 11 Pareto plot of Z-average Using Emulsions in the Statistical Design 65 
Figure 3.12 Pareto Plot of Transformed Estimates of Polydispersity index Using 
Emulsions in the Statistical Design 66 
Figure 3.13 Pareto Plot of Transformed Estimates of Zeta potential Using Emulsions in 
the Statistical Design 66 
Figure 3.14 Pareto Plot of Transformed Estimates of Dynamic Viscosity Using 
Emulsions in the Statistical Design 67 
Figure 3.15 Calibration Curve for Trifluoperazine 68 
Figure 3.16 Z-average Distribution of Emulsion 3 at day 0 71 
Figure 3.17 Z-average Distribution of Emulsion 3 after 1 week 72 
Figure 3.18 Typical Chromatogram at Day 0 1 
Figure 3.19 Typical Chromatogram of Emulsion stored at 65°C  after 1 week 74 
Figure 3. 20 HPLC Analysis of Emulsions 3 & 17 at 40ºC/ 75RH 77 
Figure 3.21 Degradation Pathway of Trifluoperazine 78 
 
  
 
 xi 
 
 
LIST OF ABBREVIATIONS 
 
 
 
AMVn  Automated Microviscometer 
AP   Aqueous Phase 
CRT   Cathode Ray Tube 
CMC   Critical Micelle Concentration 
EPC  Egg Phosphatidyl Choline 
Exp.  Experiment 
HEPC   Hydrogenated Egg Phosphatidyl Choline  
PI  Polydispersity 
P90  Phospholipon 90 
HLB  Hydrophilic- Lipophilic Balance 
HPLC   High Performance Liquid Chromatography 
Log.   Logarithm  
ODS  Octadecyl Silica  
o/w   Oil-in-water 
NMR  Nuclear Magnetic Resonance 
PVC  Polyvinyl Chloride  
SEM  Scanning Electron Microscopy  
T80  Tween 80 
TEA   Triethylethanolamine 
TEM  Transmission Electron Microscopy  
TP   Trifluoperazine 
TPN   Total Parenteral Nutrition 
 xii 
 
 
USP  United States Pharmacopeia 
Z.P  Zeta Potential 
  
1.0 Introduction  
 
1.1 Statement of the Problem 
Development of intravenous lipid emulsions began in the 1920’s; however, none of 
the early fat emulsions could be used safely in man. Since then, a very large number of 
emulsions with various lipids and emulsifiers have been investigated (1). In the early 
1960s, Arvid Wretlind and co-workers developed the first safe parenteral lipid based 
emulsion for clinical nutrition, called Intralipid
® 
(2). This product provides concentrated 
energy and essential fatty acids to patients who are unable to eat. By focusing on the 
formulation technology and the selection and purification of the lipid raw materials, this 
group of researchers overcame several adverse clinical reactions that had caused 
extensive problems for earlier investigators, including withdrawal of products from the 
market. The basic objective is to mimic as well as possible the input of chylomicrons into 
the blood. The clinical use of parenteral fat emulsions is now globally accepted as a part 
of nutrition therapy. Intralipid became the starting point for using lipid emulsions as a 
delivery matrix for lipid-soluble drugs (3, 4). 
Studies have shown that nano-emulsions can prolong drug circulation in the plasma 
by preventing drug uptake by the liver in to the reticuloendothelial system (5). Their 
potential applications range from antifungal delivery agents to immunodulators (6,7). 
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These delivery systems may also be used for localized therapy, such as in the treatment of 
lymph node metastases, or injection in to other cavities and joints (8).   
There are several advantages to the use of parenteral lipid emulsions as drug 
carriers. These include stabilization of drugs that are susceptible to hydrolysis, 
enhancement of solubility for water insoluble drugs and reduction of sorption of aqueous 
drug on plastic material of infusion set. The use of oil-in-water emulsion can improve 
aqueous solubility by incorporating the insoluble drug into the interior oil phase. Protein 
binding and hydrolytic degradation of certain drugs such as barbiturates do not occur as 
long as the drug remains in the oil phase thus further improving the therapeutic efficacy 
for emulsion formulations compared with aqueous solutions.  Direct contact of such a 
drug in a parenteral emulsion with the body fluids and tissues is reduced and the drug 
may be released slowly over a prolonged period of time; this may minimize side effects  
(9, 10, 11). 
There is a potential for sustained release of drugs from parenteral emulsion (12, 
13). Delayed absorption of the total dose from an emulsion can be achieved for drugs 
with large partition coefficient. The fraction of drug available for absorption also depends 
on the phase volume ratio between the lipid and aqueous phases in the delivery system. 
For example, if the volume of the aqueous phase is much larger than that of the oil phase, 
a large partition coefficient (w/o) will result in a small fraction of the insoluble drug 
being available for absorption and hence a sustained release effect (14). 
 
Trifluoperazine was chosen as a model drug that could be delivered in a lipid 
emulsion because of its favorable properties. It is an amphiphilic drug, therefore, a good 
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candidate for an emulsion because it will tend to localize at the oil/water interface and 
intercalate in the phospholipids monolayers due to its surface active properties (15). Its 
high log P value indicates that more of the drug will be distributed in the oil phase. 
Formulation of trifluoperazine emulsion may enhance the solubility of the drug compared 
with an aqueous formulation of the drug.  
Commercially available aqueous parenteral preparation has been reported to be 
unstable and subject to discoloration with exposure to light and sorption of 
trifluoperazine hydrochloride to infusion sets has been reported in literature. 
Trifluoperazine hydrochloride 10mg/ml in sodium chloride 0.9% exhibited a cumulative 
45% loss during a seven hour simulated infusion through an infusion set consisting of a 
cellulose propionate chamber and 170 cm of PVC tubing due to sorption. The extent of 
sorption was found to be independent of concentration. (16). An oil-in-water emulsion 
formulation of trifluoperazine may improve the delivery and chemical stability of the 
drug by reducing the likelihood of sorption of the drug on to infusion sets since most of 
the drug will be incorporated in to the oil phase of the emulsion compared with an 
aqueous formulation. Higher drug load may also be possible compared to the aqueous 
solution. This is due to its high log P as stated earlier. Therefore, the aims of the project 
were; 
1. To prepare oil-in-water emulsions for parenteral delivery using excipients which 
are generally regarded as safe (GRAS). 
2. To develop an optimal formulation with acceptable particle size in the nano range 
and evaluate other properties such as polydispersity index, zeta potential and 
viscosity. 
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3. To perform short term stability testing of the optimal formulation and monitor the 
potency using high performance chromatography (HPLC). 
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1.2 Literature Review 
1.2.1 Emulsion Technology 
An emulsion is a dispersed system containing at least two immiscible liquid 
phases. In order to ensure stability, an emulsion must contain a suitable emulsifying agent 
aside from the dispersed phase and dispersion medium (17). 
Pharmaceutical emulsions usually consist of a mixture of an aqueous phase with various 
oils and or waxes. If the oil droplets are dispersed throughout the aqueous phase the 
emulsion is termed oil-in water (o/w). A system in which the water is dispersed 
throughout the oil is termed water-in-oil (w/o) emulsion. Multiple emulsions such as 
water-in-oil-in-water (w/o/w) can be formed. In this case, small water droplets are 
enclosed within larger oil droplets, which themselves are dispersed in water. The 
alternative o/w/o is also possible (18). 
Emulsions with droplet size in the nanometric scale (typically in the range 20-
200nm) are referred to in literature as miniemulsions, nano-emulsions, ultrafine 
emulsions, submicron emulsions, etc. The term nano-emulsions is preferred because it 
gives an idea of the nanoscale size range of the droplets; it is concise and it avoids 
misinterpretation with the term microemulsion which are thermodynamically stable 
systems  (19, 20). 
Parenteral emulsions are basically prepared in two ways. One is referred to as the 
extraneous addition of a lipophilic compound to a preformed sterile fat emulsion, usually 
with the assistance of an organic solvent such as ethanol or diethyl sulfoxide. This 
method is not recommended for several reasons such as formation of large poorly 
emulsified oil droplets, undissolved drug crystals and sterility problems. The second 
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method which is the preferred method is an ab initio emulsification of drug containing oil 
phase either aseptically or in conjunction with terminal heat sterilization. Thus, emulsions 
are custom designed to accommodate the unique requirements of a particular therapeutic 
agent
 
(21). 
     
1.2.2 Mechanisms of Emulsion Formation 
In order to disperse one liquid in another in the form of an emulsion, an amount of 
work (W) in ergs/cm must be done upon the system. W is equal to the interfacial tension 
() in ergs/cm2  multiplied by the S (cm2) which is the increase in surface area of 
dispersed phase due to formation of emulsion droplets. 
SW   ……………Equation 1 
To reduce the amount of energy required for emulsification and yet obtain small droplets, 
the interfacial tension between water and oil must be lowered to a marked degree. This 
can be achieved using appropriate emulsifying agent or and homogenization. To have 
thermodynamic stability, W must be very small. This implies that the surface area and 
interfacial tension must be small. However, to have a small specific surface area, the 
droplets must be large. This could lead to aggregation or coalescence and faster 
breakdown of emulsion. Therefore, there must be a balance of the thermodynamic and 
physical stability, i.e. keeping W as minimal as possible and keeping the z-average small 
enough (22). 
Emulsion droplets are deformed and disrupted by viscous or inertial forces. 
Viscous forces generate tangential and normal stresses at the drop surface. Inertial forces 
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generate pressure differences. Laminar or turbulent flow and or cavitation forces may 
occur. In laminar flow, viscous forces are predominant. The flow can cause shear or 
elongation. In turbulent flow, inertial forces predominate; however, viscous forces may 
also be involved (23). During cavitation, small vapor bubbles are formed which 
subsequently collapse extremely fast, causing heavy shock waves in liquid. These may 
disrupt droplets. The liquid is intensely agitated and flow is turbulent. Hence, cavitation 
is comparable to disruption by turbulence. 
The occurrence of any of these mechanisms depends on the type of apparatus, 
viscosity of liquid and constructional details. The scale of the apparatus may considerably 
affect the operation. A larger machine operated at appropriate speed gives more 
turbulence.  
Emulsion droplets may also be disrupted due to interfacial instability caused by 
surface tension gradients. This is dependent on the surfactant and can occur in any 
equipment (24). 
Emulsions can be prepared by high energy emulsification methods which includes 
high pressure homogenization and ultrasound generators or by low energy emulsification 
methods such as spontaneous emulsification or solvent diffusion method and phase 
inversion temperature (PIT) method (25).  
 
1.2.2.1 Emulsification by Ultrasonication.   
Emulsions can be produced using a sonicator, a laboratory equipment that 
generates ultrasonic waves. This type of sonicator has an ultrasonic transducer which 
consists of piezoelectric crystal contained within a protective metal casing. Application of 
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a high electrical wave to the transducer causes the piezoelectric crystal to rapidly oscillate 
and generate an ultrasonic wave.
 
At the beginning of emulsification, waves are produced 
at the interface giving rise to fairly coarse drops. During this process of emulsification by 
ultrasound, cavitation or formation of cavities by liquid and their subsequent collapse 
occur accompanied by intense hydraulic shocks. (Figure 1.1) The exact mechanism of 
droplet break up is unknown. Postulations are that the droplet oscillates at a natural 
frequency until it bursts (26).
  
 
Figure 1. 1 Mechanism of Cavitation in Emulsification by Ultrasound (27) 
(Cavity C collapses in the vicinity of droplet O) 
Drug emulsions for parenteral delivery have been prepared by sonication. J. 
Medina et al. studied the development of a parenteral emulsion formulation for 
lorazepam using sonication (28). Jafari and coworkers  evaluated the efficiency of 
sonication and microfluidization in the production of d-limonene oil-in-water nano-
emulsions and observed that the size of the emulsions decreased with increasing 
sonication time and also produced emulsions in the size range of 150-700nm (29). 
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1.2.2.2 Emulsification using High Pressure Homogenizers.  
Homogenizers may be used in one of two ways; 1.) By mixing ingredients in the 
emulsion and then passing those through the homogenizer to produce the final product 
and 2.) Produce a coarse emulsion first using a different method then passing it through a 
homogenizer.  The purpose is to decrease droplet size and obtain a greater degree of 
uniformity and stability. The homogenizers operate at pressures of 1000 to 5000 psi to 
produce some of the finest dispersions obtainable in an emulsion (30). 
 
1.2.2.3 Phase Inversion Method.  
Phase inversion in emulsions can be one of two types: transitional inversion or 
catastrophic inversion (31). These methods make use of changing the spontaneous 
curvature of the surfactant. For non-ionic surfactants, phase inversion can be achieved by 
changing the temperature of the system, forcing a transition from an oil-in-water (O/W) 
emulsion at low temperatures to a water-in-oil (W/O) emulsion at higher temperatures 
(transitional phase inversion). During cooling, the system crosses a point of zero 
spontaneous curvature and minimal surface tension, promoting the formation of finely 
dispersed oil droplets. Catastrophic inversion is a transition in the spontaneous radius of 
curvature that can be obtained by changing the volume fraction of the phase. By 
successively adding water into oil, initially water droplets are formed in a continuous oil 
phase. Increasing the water volume fraction changes the spontaneous curvature of the 
surfactant from initially stabilizing a W/O emulsion to an O/W emulsion at the inversion 
locus. This process is well known for short-chain surfactants which form flexible 
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monolayers at the oil–water interface, resulting in a bicontinuous microemulsion at the 
inversion point (32). 
 
1.2.3 Characterization of Emulsions 
Characterization of nano-emulsions is of utmost importance in order to ensure the 
production of emulsions which fall within the desired droplet size range, viscosity and 
charge and are stable with time. Several techniques have been developed to characterize 
emulsions such as particle size analysis, polydispersity and zeta potential determination, 
differential scanning calorimetry, nuclear magnetic resonance (NMR), HPLC, viscosity 
and surface tension determination.  Some of these methods will be highlighted below. 
 
1.2.3.1 Particle size determination 
Particle size of emulsions can be determined using several techniques. Some of 
the major techniques are hydrodynamic chromatography, photon correlation 
spectroscopy, spectroturbidimetry, field flow fractionation, sensing zone, electron 
microscopy and sedimentation (33).  
 
1.2.3.1.1  Photon Correlation Spectroscopy 
  Photon correlation spectroscopy is also known as dynamic light scattering. The 
principle of operation is based on the intensity of the light scattered from dispersions of 
particles and macromolecules. This intensity fluctuates with time and are too rapid and 
shift too little to be evident to the human eye. The pace of the movement of particles is 
inversely proportional to the particle size and can be detected by analyzing the time 
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dependency of the light intensity fluctuations scattered from particles when they are 
illuminated with a laser beam. The time dependence of the light scattered from a very 
small region of solution over a time range from 10
th
 of a microsecond to milliseconds is 
measured. These fluctuations in intensity are related to the rate of diffusion of particles in 
and out of the region being studied (Brownian motion), and the data can be analyzed to 
directly give the diffusion coefficients of the particles doing the scattering. The data are 
processed to give the ―size‖ of the particles (radius or diameter) which is based on the 
theoretical relationship between the Brownian motion and the size of the spherical 
particles (34). This is based on the Stokes-Einstein equation.   
d
kT
Do
3
 -----------------Equation 2 
where oD  is the diffusion coefficient,   is the viscosity of the suspending medium, and 
d  is the particle diameter (35). The instrumentation for photon correlation spectroscopy 
shown in Figure 1.2 consists basically of a light source, which is either argon or helium-
neon laser, a spectrometer consisting of an optical system for defining the scattering 
angle and limiting the number of coherence areas, a detector (usually a photomultiplier), 
a signal analyzer which is a digital autocorrelator and a computer for processing and 
displaying the data (36). Instruments such as Malvern Zetasizer Nanoseries® (Malvern 
Instruments, UK) and Nicomp® particle sizer (Particle Sizing Systems, CA) are available 
for measurement of particle size.  
The diameter that is measured in dynamic light scattering is the hydrodynamic 
diameter, known as z-average. Z-average is the mean hydrodynamic diameter and is 
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calculated according to the international standard on dynamic light scattering ISO 13321. 
It is intensity weighted so it is sensitive to the presence of large particles (37). 
 
 
 
Figure 1. 2 Schematic diagram of a PCS instrument (38) 
 
 
 
1.2.3.1.3 Electron Microscopy Techniques 
Scanning electron microscopy and transmission electron microscopy are 
important techniques in emulsion characterization. Microscopic techniques allow 
determination of both particle size and distribution, and observation of particle shape. In 
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addition, other parameters, such as morphology or surface roughness can be observed 
(39). 
 
1.2.3.1.3.1 Scanning Electron Microscopy 
Scanning electron microscopy (SEM) is one of the most widely used techniques 
used in characterization of nanomaterials and nanostructures. The resolution of the SEM 
approaches a few nanometers, and the instruments can operate at magnifications that are 
easily adjusted from - 10 to over 300,000. SEM produces topographical information and 
the chemical composition information near the surface. In a typical SEM, a source of 
electrons is focused into a beam, with a very fine spot size of 5 nm and having energy 
ranging from a few 100 eV to 50 Kev that is rastered over the surface of the specimen by 
deflection coils. As the electrons strike and penetrate the surface, a number of 
interactions occur that result in the emission of electrons and photons from the sample. 
SEM images of the emitted electrons are consequently produced on a cathode ray tube 
(CRT) (40). 
 
1.2.3.1.3.2 Transmission Electron Microscopy (TEM)   
In TEM, electrons are accelerated to 100 KeV or higher (up to 1 MeV), projected 
onto a thin specimen (less than 200nm) by means of the condenser lens system, and 
penetrate the sample thickness either undeflected or deflected. The greatest advantages 
that TEM offers are the high magnification ranging from 50 to10
6 
and its ability to 
provide both image and diffraction information from a single sample. 
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1.2.3.2 Polydispersity Index 
The second characterization of emulsion to be discussed is the polydispersity 
index. Photon correlation spectroscopy can also be used to determine the polydispersity 
index of an emulsion using the Malvern
 
Zeta sizer. This is necessary to characterize the 
particle size distribution of an emulsion. Polydispersity is the width of particle size. A 
narrow size distribution, corresponding to a polydispersity index between 0.1 and 0.2, is 
generally found with colloidal drug carriers. Larger polydispersity indices indicate a 
broad size distribution. 
 
1.2.3.3 Zeta Potential Determination 
Zeta potential is a measurement of surface potential. The magnitude of zeta 
potential gives an indication of potential stability of an emulsion (41). Zeta potential is an 
important parameter in determining the stability of an emulsion and other colloidal 
dispersions; zeta potential larger than about 25 mV is typically required to stabilize a 
colloidal system. Zeta potential is determined by a number of factors, such as the particle 
surface charge density, the concentration of counter ions in the solution, solvent polarity 
and temperature (42). Zeta potential can be determined using the Malvern Zeta sizer or 
the Nicomp particle sizer. Zeta potential is determined by electrophoretic light scattering 
(ELS). The Smoluchowski equation can be used to compute the zeta potential from 
electrokinetic mobility µ. 
------------Equation 3 
where  is the permittivity and  the viscosity of the liquid used. (43) 
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 1.2.3.4 Viscosity Determination 
Viscosity is defined as a measurement of the applied stress per unit area required 
to maintain a certain flow rate or shear rate. In general, viscosity is the resistance to liquid 
flow, whereas fluidity is the reciprocal of viscosity or the coefficient of viscosity. Thicker 
liquids have higher the viscosities while thinner the liquids have lower viscosities or 
higher fluidity (44). Two types of viscosity may be specified: dynamic viscosity   and 
kinematic viscosity . Dynamic viscosity is the absolute viscosity of the emulsion and the 
kinematic viscosity is obtained by dividing the dynamic viscosity by the density of the 
liquid. The kinematic viscosity is the viscosity due to the influence of gravity. They are 
related by the expression    where   is the density of the fluid (45). Viscosity can 
be determined by several methods such as rotational, falling or rolling ball, capillary tube 
or orifice and surface viscosity methods. 
 
1.2.3.4.1 Rolling ball Viscometer 
The rolling ball viscometer operates based on Stoke’s law. When a body falls 
through a viscous medium it experiences a resistance or viscous drag which opposes the 
downward motion. Consequently if a body falls through a liquid under the influence of 
gravity, an initial acceleration period is followed by motion at a uniform terminal velocity 
when the gravitational force is balanced by the viscous drag (46). 
The Stoke’s equation can be used to determine the viscosity of the liquid as given below.  



18
)(2 lsgd  ……………..Equation 4 
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Where  is viscosity, d is diameter of sphere, s is density of sphere, l is density of 
liquid, g is acceleration due to gravity and  is terminal velocity. 
Terminal velocity (  ) is determined when a liquid is placed in the fall tube which is 
clamped vertically in a constant temperature bath. Sufficient time must be allowed for 
temperature equilibration and for air bubbles to rise to the surface.  A steel sphere is 
introduced into the fall tube through a narrow guide tube. The passage of the sphere is 
monitored and the time it takes to fall is recorded. 
 
1.2.3.4.2 Capillary Viscometer 
The rate of flow of the fluid through the capillary is measured under the influence 
of gravity or an externally applied pressure. Liquid is allowed to flow under gravity from 
a reservoir through a tube of known cross-section. In different instruments, the tube can 
vary from capillary size to a large diameter. The pressure difference across the ends of 
the tube and the time for a given quantity of flow are measured, and then the liquid 
viscosity for Newtonian fluids can be calculated as  
 
LV
PTR
Cv
425.1 
 ……………….Equation 5 
Where R is the radius (m) of the tube, L is its length (m), P is the pressure difference 
(N/m
2
) across the ends and V is the volume of the liquid flowing in time T (m
3
/s) (47). 
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1.2.3.4.3 Rotational Viscometer 
The rotational viscometer involves concentric cylinder and cone and plate 
instruments. An approximation to uniform rate of shear throughout the sample is 
achieved by shearing a thin film of the liquid between concentric cylinders. The outer 
cylinder can be rotated or oscillated at a constant rate and the shear stress measured in 
terms of the deflection of the inner cylinder, which is suspended by a torsion wire or the 
inner cylinder can be rotated with the outer cylinder stationary and the resistance offered 
by the motor measured. This method is useful for studying the flow behavior of non-
Newtonian liquids and highly viscous materials (48). The viscosity in poise (CV) for 
Newtonian liquids is given by 
h
RR
GCv



2
2
2
1 /1/15.2 ------------Equation 6 
Where G is the couple formed by the torsion wire and its deflection, R1 and R2 are the 
radii of the inner and outer cylinders; h is the length of the cylinder and  is the angular 
velocity (rads/s) of the rotating cylinder. (49) 
   
 
1.2.4 Emulsion Components and Functionalities 
1.2.4.1 Trifluoperazine 
 The IUPAC Chemical name of trifluoperazine is 10-[3-(4-methylpiperazin-1-
yl)propyl]-2-(trifluoromethyl)-10H-phenothiazine. Trade names are Iatroneural

, 
Jatroneural

, Eskazinyl

, Eskazine

, Stelazine

 and Terfluzine

. It is a white to off 
white crystalline powder with little or no odor (53, 54, 55). Trifluoperazine has surface 
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active properties. The critical micellar concentration (CMC) of trifluoperazine is 4.2 x 10
-
5
. The CMC increases with increasing pH, due to protonation of the second nitrogen atom 
of the drugs’ piperazine ring (56). 
Trifluoperazine hydrochloride is a phenothiazine antipsychotic used in the 
treatment of a variety of psychiatric disorders including schizophrenia severe anxiety, and 
disturbed behavior. It is also used for the control of nausea and vomiting. It is effective 
for the short-term treatment of generalized non-psychotic anxiety. Trifluoperazine is 
given as the hydrochloride but its doses are expressed in terms of the base. 1 mg of 
trifluoperazine is approximately equivalent to 1.2 mg of trifluoperazine hydrochloride 
(57).  
 
 
Figure 1. 3 Structure of Trifluoperazine 
 
The usual initial dose for the treatment of schizophrenia and other psychoses is 2 
to 5 mg twice daily by mouth, gradually increased to a usual range of 15 to 20 mg daily. 
In severe or resistant psychoses, daily doses of 40 mg or more have been given. For the 
control of acute psychotic symptoms it may be given by deep intramuscular injection in a 
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dose of 1 to 2 mg, repeated if necessary at intervals of not less than every 4 hours; more 
than 6 mg daily is rarely required. The initial dose for use in children is up to 5 mg daily 
by mouth in divided doses adjusted according to age, body-weight, and response, or 1 mg 
given once or twice daily by intramuscular injection (57). 
For the control of nausea and vomiting, the usual adult dose by mouth is 1 or 2 mg twice 
daily; up to 6 mg daily may be given in divided doses. Children aged 3 to 5 years may be 
given up to 1 mg daily in divided doses; this may be increased to a maximum of 4 mg 
daily in children aged 6 to 12 years. When used as an adjunct in the short-term 
management of severe anxiety disorders, doses are similar to those used for the control of 
nausea and vomiting (55).  
In recent studies trifluoperazine, a calmodulin antagonist has also been reported as 
effective in T-cell recovery of HIV patients. It binds to Ca
(2+)
-calmodulin at high 
concentrations, it was found at low concentrations (10
-6
 to 10
-10
 M) to help T-cells from 
AIDS patients to restore proliferation in vitro (56, 57). Trifluoperazine also showed some 
significant antimicrobial activity.  Forty six of 55 strains of Staphylococcus aureus were 
inhibited by 10–50 μg/ml of trifluoperazine. This drug  also inhibited strains of Shigella 
species, Vibrio cholerae and Vibro parahaemolyticus at a concentration of 10–100 μg/ml. 
Other bacteria including Pseudomonas species were moderately sensitive to 
trifluoperazine (58). Preclinical studies have also shown that trifluoperazine can suppress 
opioid tolerance due to its inhibition of calcium/calmodulin dependent protein kinase II 
(59). 
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1.2.4.2 Soybean oil 
Soybean oil is defined by the USP 26 as the refined fixed oil obtained from the 
seeds of the Soya plant Glycine soja (Leguminosae). In pharmaceutical preparations, 
soybean oil emulsions are primarily used as a fat source in total parenteral nutrition 
(TPN) regimens. Although other oils, such as peanut oil, have been used for this purpose, 
soybean oil is now preferred because it is associated with fewer adverse reactions (60). 
Soybean oil is used as an oleaginous solvent in the preparation of the oil-in-water 
emulsions. Fatty acid composition of soybean oil is shown in Table 1.1. It has a viscosity 
of 49mPas at 25C. 
 
Table 1.1  Fatty acid composition of soybean oil 
 
Fatty acid Percentage Composition 
Palmitic acid 7-14% 
Stearic acid 1-6% 
Oleic acid 19-30% 
Linoleic acid 44-62% 
 
  
1.2.4.3 Tricaprylin 
Tricaprylin is a medium chain triglyceride. Other names include glyceryl 
tricaprylate; trioctanoin; caprylic acid triglyceride; 1,2,3- trioctanoylglycerol. It is an 
odorless, colorless to light yellow liquid.  Molecular weight of 470.69 g/mole.  
 
 
 
 
21 
 
 
 
Figure 1. 4 Chemical Structure of Tricaprylin (61). 
 
 
1.2.4.4 Tributyrin 
  Tributyrin is also known as glyceryl tributyrate. It is prepared by esterification of 
glycerol with excess butyric acid. Chemical abstract service (CAS) name is Butanoic acid 
1,2,3-propanetriyl ester. Its molecular formula is C15H26 O6 and it has a molecular weight 
of 302.36. It is an oily liquid with bitter taste, insoluble in water but very soluble in 
alcohol and ether (62). 
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Figure 1. 5 Chemical Structure of Tributyrin  
 
 
1.2.4.5 Ethyl Oleate 
 Other names include Ethyl 9-octadecenoate; oleic acid, ethyl ester. The chemical 
name is (Z)-9-octadecenoic acid, ethyl ester. The empirical formula is C20H3802. Ethyl 
oleate occurs as a pale yellow to almost colorless mobile oily liquid with a taste 
resembling that of olive oil. It is primarily used as a vehicle in parenteral preparations 
intended for intramuscular administration. It is a suitable solvent for steroids and other 
lipophilic drugs. It is less viscous than fixed oils and is more rapidly absorbed by body 
tissues (63). 
 
Figure 1. 6 Chemical Structure of Ethyl Oleate 
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1.2.4.6 Phosphatidyl choline 
  Phosphatidyl choline, also known as lecithin is a phospholipid which is a 
naturally occurring emulsifier obtained from either egg yolk or Soya beans. There several 
brands of lecithin available with different percentages of pure phosphatidyl choline. 
Hydrogenated egg phosphatidyl choline usually contain about 99% of phosphatidyl 
choline while soy derived phosphatidyl choline contains about 90%. 
Phospholipids are biological surfactants with two hydrocarbon tails (the R groups) 
and a hydrophilic head (the phosphate salt group). Phosphatidyl choline is regarded as 
safe for parenteral use. It can be biodegraded and metabolized, since it is an integral part 
of biological membranes making it virtually non-toxic (64). 
 
 
 
Figure 1. 7 α-phosphatidyl choline 
 
(R1 and R2 = C15-C17 hydrocarbon chains) 
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Phosphatidyl choline surfactant molecules have the ability to give necessary 
curvature of the interfacial film required to form nano-emulsions or microemulsions and 
this has been related to its packing geometry, which is the ratio of packing between the 
hydrocarbon volume, optimum head group area and tail length of the molecule at the 
surface. Phosphatidyl choline has a packing parameter around 0.8; this value is further 
increased if the oil phase penetrates into the alkyl chains of the lecithin molecule. In order 
to produce oil-in-water emulsions in the nano range, it is necessary to reduce this 
parameter by using co-surfactants or partial substitution of phosphatidyl choline by a 
more hydrophilic emulsifier (65). 
 
 
1.2.4.7 Polysorbate 80 
Polysorbate 80 (Chemical name: Polyoxyethylene 20 sorbitan monooleate, 
Chemical formula C64H124O26) is a non-ionic surfactant also referred to as Tween 80. It is 
an oleate ester of sorbitol and its anhydrides copolymerized with approximately 20 moles 
of ethylene oxide for each mole of sorbitol and sorbitol anhydrides. It has a HLB value of 
15 and as a result is used in the production of oil-in-water emulsions (66). 
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Figure 1. 8 Chemical Structure of  Polyoxeyethylene sorbitan monoester  
Polysorbate 80 (w + x + y + z = 80) 
 
 
1.2.5   Statistical Experimental Design. 
Experimental design can be defined as the strategy for setting up experiments in 
such a manner that the information required is obtained as efficiently and precisely as 
possible. Experimentation is carried out to determine the relationship between the factors 
acting on the system and the response or the properties of the system. This information 
was used to further and achieve the aims of the project (67). 
Statistical tests provide the tools by which decisions can be made. Factorial 
designs are used in experiments where the effects of different factors, or conditions on 
experiments are to be elucidated (68). It is the design of choice for simultaneous 
determination of the effects of several factors and their interactions. Factorial designs 
have maximum efficiency in estimating main effects. If interaction exist, a factorial 
design is necessary to reveal and identify the interactions. Since factor effects are 
measured over varying levels of other factors, conclusions apply to a wide range of 
conditions. Maximum use is made of data since all main effects and interactions are 
independent of effect of other factors (69). 
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1.2.6 Stability Studies of Emulsions 
The stability of any pharmaceutical product is defined as the capacity of the 
formulation to remain within defined limits for a predetermined period of time (shelf life 
of the product). The first step to designing any type of stability testing program is to 
specify these limits by establishing parameters defined in terms of chemical stability, 
physical stability and microbial stability. Next, methods must be established to evaluate 
these parameters (70). 
Emulsions are thermodynamically unstable exhibiting flocculation and 
coalescence unless significant energetic barriers to droplet interactions are present. 
Emulsions are sensitive to coarsening phenomena like coalescence and Ostwald ripening 
since droplet size is not uniform and concentration gradients drive mass exchange, thus 
inducing changes in droplet sizes (71). Forced degradation studies involve subjection of 
emulsions to harsh conditions such as elevation of temperature. Emulsion characteristics 
are determined before and after the tests. As discussed in the experimental section, 
stability of emulsions were determined using the stress tests and accelerated stability 
studies of emulsions based on ICH guidelines were also determined. Stress tests included 
centrifugation and freeze thaw cycles of emulsions. Emulsion characteristics were 
determined before and after the tests. 
 
 
1.2.6.1 Physical Instability 
Instability of lipid emulsions can arise from changes in particle size of oil droplets 
leading to creaming and coalescence or from changes in pH, hydrolysis of emulsifier, or 
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oxidation of oil (72). There are basically 5 ways in which the structure of a dispersion of 
liquid droplets in a continuous medium can change resulting in physical instability. 
 
1.2.6.1.1 Creaming 
Creaming is the upward movement of dispersed droplets relative to the 
continuous phase. There is no change in droplet size, but buildup of an equilibrium 
droplet concentration gradient within the emulsion. This phenomenon occurs from 
external force fields, usually gravitational, centrifugal or electrostatic, acting on the 
system. The disperse phase, according to its density relative to that of the continuous 
phase, rises to the top or sinks to the bottom of the emulsion, forming a concentrated 
layer at the top of the emulsion. Sedimentation involves the same process but in the 
opposite direction (73). 
 
1.2.6.1.2 Flocculation 
In flocculation of emulsion droplets, there is no change in droplet size or 
distribution but the buildup of aggregates of droplets within the emulsion. Flocculation 
results from the existence of attractive forces between the droplets. 
 
1.2.6.1.3 Coalescence 
 Emulsion droplets within a close- packed array resulting from sedimentation or 
creaming, coalesce to form larger droplets. This results in a change in the initial droplet 
size distribution. 
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1.2.6.1.4 Ostwald Ripening 
Larger emulsion droplets are formed at the expense of the smaller droplets. In 
principle, the system will tend to an equilibrium state in which all the all the droplets 
attain the same size. Ostwald ripening is associated with the difference in chemical 
potential for emulsion of different size (74). 
 
1.2.6.1.5 Phase Inversion 
 This is the process where an emulsion changes for example from an o/w 
emulsion to a w/o emulsion. This may be brought about by a change in temperature or 
concentration of one of the components or by the addition of a new component to the 
system  (75, 76). 
 
1.2.6.2 Chemical Instability 
Chemical instability of an emulsion may occur as a result of drug degradation. 
Possible degradation pathways include hydrolysis, dehydration, isomerization and 
racemization, elimination, oxidation, photodegradation, and complex interactions with 
excipients and other drugs (77). The degradation pathway depends on the chemical nature 
of the drug.  Trifluoperazine is a phenothiazine that is easily oxidized. It is subject to air 
and light induced oxidative degradation. The mechanism can be considered a two-step 
reaction involving the intermediate formation of a semiquinone free radical, which is then 
oxidized to the sulfoxide (78). 
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1.2.6.3 Regulatory Guidelines for Evaluation of Emulsion Stability 
The International conference on harmonization (ICH) of technical requirements 
for registration of pharmaceuticals for human use regulates the stability test by which 
emulsions and other drug products should be evaluated. This includes stress testing, long 
term, intermediate or accelerated stability studies.  
Stress testing of the drug substance can help identify the likely degradation 
products, which can in turn help establish the degradation pathways and the intrinsic 
instability of the molecule and validate the stability indicating power of the analytical 
procedures used.  
ICH guidelines recommend stress test on a single batch of the drug substance. It 
should include the effect of temperatures (in 10°C increments (e.g., 50°C, 60°C, etc.) 
above that for accelerated testing), humidity (e.g., 75% RH or greater) where appropriate, 
oxidation, and photolysis on the drug substance. The testing should also evaluate the 
susceptibility of the drug substance to hydrolysis across a wide range of pH values when 
in solution or suspension. Photostability testing should be an integral part of stress testing 
(82).  
ICH guidelines for accelerated stability studies includes testing at 40

C ± 2

C/75% 
RH± 5% RH for a minimum period of 6 months, intermediate studies at 30

C ± 2

C/65% 
RH ± 5% RH  for at least 6 months and long term stability studies at 25

C ± 2

C/60% RH 
± 5% RH or 30

C ± 2

C/65% RH ± 5% RH for a period of 12 months on at least three 
primary batches (79). 
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2.0  Experimental 
 
2.1 Materials 
Soybean oil was purchased from Nacalai Tesque, Japan.  Polysorbate 80 (Tween 
80) was purchased from Spectrum Chemicals, New Brunswick, NJ.  
Ethyl oleate, tricaprylin and tributyrin were also purchased from Spectrum chemicals. 
Hydrogenated egg phosphatidyl choline (HEPC) and Phospholipon 90

 (Soybean 
lecithin) were donated by Avanti Polar Lipids, Alabaster, AL and Natterman 
Phospholipid GMBH, Germany respectively. Trifluoperazine hydrochloride was obtained 
from Spectrum Chemicals, NJ. HPLC grade acetonitrile, monobasic ammonium 
potassium phosphate and chloroform were obtained from Fisher Scientific, Pittsburgh, 
PA as shown in Table 2.1. A list of the equipments used for the experiments is shown in 
Table 2.2 
 
2.2 Methodology 
 
2.2.1 Preparation of Nano-emulsions 
 
2.2.1.1 Thin Layer Hydration Method 
Soybean oil, polysorbate 80 (Tween 80), phosphatidylcholine and the drug were 
accurately weighed into a 50ml flask.  An appropriate volume of chloroform was added 
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to dissolve the materials in the flask. Chloroform was evaporated from the solution using 
a Buchi Rotavapor at a temperature of 35 degrees. After evaporation of solvent, the 
emulsion film was dried in a desiccator for at least 3 hours to remove any residual 
solvent. An appropriate volume of sterilized Millipore

 water was added to the film flask 
using a disposable plastic syringe through a 0.22m membrane filter. The flask opening 
was covered with a rubber closure. Two needles were inserted in to the rubber closure.  
Nitrogen gas was introduced into the glass through a rubber tube for 30 seconds to 
prevent oxidation of phosphatidyl choline. The nano-emulsion was formed through a 
series of sonication and vortex. This method has been previously described in literature 
(80). 
 
2.2.2 Preliminary Emulsion Formulations 
The preliminary experiments were screening experiments carried out prior to 
selection of emulsion components. Four different oil phases: soybean oil, ethyl oleate, 
tricaprylin and tributyrin were used in order to select the most suitable oil phase for the 
emulsion. Phosphatidyl choline was obtained from six different sources: soy lecithin, 
hydrogenated egg phosphatidyl choline, phospholipon 90 G, phospholipon 90 H, lipoid 
EPC and lipoid EPC-3 were used for the preliminary formulations (Table A1).   
 
2.2.3 Optimization of Emulsion Components       
After the preliminary emulsions were produced, more emulsions were formulated 
to determine the outcome of optimizing the concentration of the emulsion components.  
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The first set of emulsions were prepared in an Oil:Tween 80 weight ratio of 1:1, 
2:1 and 3:1 at 9%, 16% and 23w/w% (oil/oil+water) soybean oil concentration. Emulsion 
composition is shown in Table 2.3. Each emulsion was replicated to validate the z-
average, zeta potential and polydispersity index data. The effect of increasing 
concentration of phosphatidyl choline was evaluated and emulsion composition is shown 
in Table 2.4. The concentration of Tween 80 was also varied, formulation composition of 
emulsion is shown in Table 2.5. Drug content of emulsion was optimized by increasing 
trifluoperazine concentration and evaluating the outcome on emulsion characteristics, 
formulation composition is shown in Table 2.6. Phase diagrams were plotted to show the 
boundaries of the optimal formulation. 
 
                                                                                                                                                                                    
2.2.3 Z-average analysis, polydispersity index and zeta potential 
determination 
Size, polydispersity index and zeta potential were simultaneously determined 
using the Zeta sizer® (Malvern instruments, Westborough, MA) and Nicomp380 ZLS® 
particle sizer (Santa Barbara, CA). Both instruments operate based on photon correlation 
spectroscopy. 1ml of Soybean emulsion was diluted to 50ml with Millipore water prior to 
z-average, zeta potential and polydispersity analysis. Disposable cuvettes were used.  
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Figure 2. 1 Branson
®
 Sonicator 
 
 
    Figure 2. 2 Buchi Rotavapor® 
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Table 2.1  List of Materials 
 
 
 
 
 
 
 
 
 
 
 
 
 Material Manufacturer Lot.  no 
1. Polysorbate 80 Spectrum Chemical 
Manufacturing Company  
TR0021 
2. Trifluoperazine HCl Spectrum Chemical 
Manufacturing Company 
SK0706 
3.  Soybean Oil Nacalai Tesque, Japan M2G4769 
4.  Phospholipon 90 H Natterman Phospholipid GMBH 00250 
5. -Phosphatidylcholine Avanti Polar Lipids 830051P 
6. Lipoid EPC Lipoid GMBH 105023 
7 Lipoid EPC 3 Lipoid GMBH 276015-1 
8 Phospholipon 90G Natterman Phospholipid GMBH 10460 
9. Ammonium phosphate monobasic Fisher Scientific, Pittsburgh, PA 954716 
10. Acetonitrile HPLC grade Fisher Scientific, Pittsburgh, PA 954716 
11. Chloroform Fisher Scientific, Pittsburgh, PA 973219 
12. Millipore water Millipore corporation  
 35 
Table 2.1  List of Equipments 
 
Equipment Company Model No Serial No 
Buchi Rotavapor Brinkmann Instruments Inc Westbury, NY.  R-200 411713045011 
Branson Sonicator Branson Ultrasonics Corporation, Danbury, CT 2510R-DTH RLC050384967
Shimadzu HPLC system Shimadzu Scientific Instruments Inc., Columbia, SCL-10A 20161E 
Shimadzu HPLC Auto injector Shimadzu Scientific Instruments Inc., Columbia, SIL-10A 20218F 
Shimadzu HPLC  Shimadzu Scientific Instruments Inc., Columbia, SPD-10A 200936 
Guard Column Phenomenex, Torrance, CA 03A-0082- 2619281 
Column Phenomenex, Torrance, CA Sphereclon 206197-3 
Shimadzu HPLC Shimadzu Scientific Instruments Inc., Columbia, LC-10AS 20226A 
Automated Microviscometer ANTON PAAR, Ashland VA AMVN 581875 
Microcentrifuge Denver Instrument Company  M005948 
Equipment Company Model No Serial No 
Mechanical Convection Oven Precision Scientific Inc.Chicago, IL STM 80 11RU-11 
Equipment Company Model No Serial No 
Nicomp Particle Sizer Particle Sizing systems , Santa Barbara USA 3802LS 9805302 
Malvern Zeta Sizer Malvern Instruments 3000-HS  
Zeta sizer Nano ZS Malvern Instruments Nanoseries  
Fisher Scientific Low Fisher Scientific, Pittsburgh, PA 307A 4100332 
Denver Instruments Balance Denver Instruments Company, Arvada, CO AB-120 B044193 
Denver Instruments Balance Denver Instruments Company, Arvada, CO 400 0058954 
pH Meter VWR Scientific Products, West Chester, PA 9100 1013 
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Table 2.3  Formulation Composition: Effect of Surfactant to Oil Ratio 
 
Oil:Tween 80 ratio P.90 (mg) Water (ml) Trifluoperazine (mg) 
1:1 250 10 40 
2:1 250 10 40 
3:1 250 10 40 
 
 
 
 
Table 2.4  Formulation Composition: Effect of Phosphatidyl choline 
Oil:Tween 80 ratio P. 90 (mg) Water (ml) Trifluoperazine (mg) 
1:1 100 10 40 
1:1 250 10 40 
1:1 500 10 40 
1:1 750 10 40 
 
 
 
 
 
Table 2.5  Formulation Composition: Effect of Tween 80 
 
T.80 (mg) P. 90 (mg) Soy.Oil (mg) Water (ml) 
(ml) 
Trifluoperazine(mg) 
300 250 1000 10 40 
650 250 1000 10 40 
1000 250 1000 10 40 
 
 
 
 
Table 2.6  Effect of Drug Content 
Oil:Tween 80 ratio P.90 (mg) Water (ml) 
(ml) 
Trifluoperazine(mg) 
1:1 250 10 40 
1:1 250 10 60 
1:1 250 10 80 
1:1 250 10 120 
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2.2.4 Viscosity Determination 
  Dynamic and kinematic viscosities of the emulsions were determined using the 
Automated Microviscometer® (Anton Paar, Ashland, VA). The AMVn® is an automated 
high precision viscometer. It utilizes the rolling ball technique. Viscosity of emulsions 
were  determined as shown in the diagram below (Figure 2.3) by observing the rolling 
time of a solid sphere under the influence of gravity in an inclined cylindrical tube filled 
with a sample liquid. The time taken by the ball to travel the fixed distance is measured 
with two inductive sensors. For each single rolling time, the result can be expressed as 
dynamic viscosity (mPa/s) and kinematic viscosity (mm
2
/s) if sample density is known 
(81). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 Automated Microviscometer (AMVn) 
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2.2.5 Ternary Phase Diagrams 
In order to produce phase diagrams, over 50 different emulsions were prepared 
and characterized using the modified thin layer hydration method as previously 
described. The existence of nano-emulsion phase was identified as the area in the phase 
diagrams where clear and transparent formulations are obtained, based on visual 
inspection of many samples (82). Emulsions which had z-average less than 70nm and 
zeta potential greater than 25mV were selected as representative emulsions. These 
emulsions were selected because of transparence, relatively small z-average and high zeta 
potential, factors that indicate the potential stability of emulsions. 
 A phase diagram of representative emulsions (shown under the Results and Discussion 
section (Page 57) was plotted using JMP
®
 software. 
 
2.2.6. Statistical Design 
The results obtained from the phase diagrams were used to develop a statistical 
experimental design. The phase diagram data showed the effect of different compositions 
of emulsion components on the emulsion characteristics. Based on these data, two levels 
were selected (high level and low level) for each component (factor) of the emulsion as 
shown in Table 2.7. A completely randomized 2X2X2X2X2 full factorial design 
experimental design was developed using JMP
®
 software (Table 2.8).  
This design enables testing of the main effects due to formulation factors of the 
emulsion, determination of the possibility of interactions within the model and the 
significance of these factors and the interaction terms. The factors were the emulsion 
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components such as Tween 80, soybean oil, Phospholipon 90G
®
, trifluoperazine and 
Millipore water. The dependent variables were z-average, zeta potential, polydispersity 
index, dynamic viscosity and kinematic viscosity of the emulsions. JMP
®
 software was 
used to fit the model for each of the dependent variables. The p-values as shown under 
Results and Discussion (Page 59) indicate the level of significance of the factors. Pareto 
charts were plotted as graphical representations of the significance of the factors. 
 
 
 
Table 2.7  Experimental Design Factors 
Factors Level 
High Low 
Tween 80 1000mg 300mg 
Phospholipon 90 750mg 250mg 
Soybean Oil 3000mg 1000mg 
Millipore Water 20ml 10ml 
Trifluoperazine 120mg 40mg 
 
 
2.2.7 High Performance Liquid Chromatography (HPLC) Analysis and 
Method Development 
Several techniques have been utilized by researchers for HPLC analysis of 
phenothiazines. HPLC analysis is useful in determination of the stability of drug 
emulsions and identification of degradation products of trifluoperazine. A. Gindy et al. 
presented 3 methods for the determination of trifluoperazine in the presence of its 
degradation products (83). Many HPLC procedures have been described for the 
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determination of trifluoperazine singly or in combination with other phenothiazines (84-
87) HPLC analysis  was based on modification of a published method (87-90).  
 
Table 2.8 2X2X2X2X2 Full Factorial Experimental Design 
Experiment T. 80 
(mg) 
P. 90 (mg) Soy. Oil 
(mg) 
Millipore 
water 
(ml) 
Drug (mg) 
1 300 750 3000 20 120 
2 300 750 3000 10 40 
3 1000 250 1000 20 40 
4 300 250 1000 20 120 
5 1000 750 3000 20 120 
6 1000 750 1000 20 120 
7 300 750 3000 20 40 
8 300 750 1000 10 120 
9 300 250 1000 20 40 
10 1000 250 3000 20 120 
11 1000 750 1000 10 40 
12 300 250 1000 10 40 
13 300 250 1000 10 120 
14 1000 250 1000 20 120 
15 300 250 3000 20 40 
16 1000 250 3000 20 120 
17 1000 250 1000 10 40 
18 300 250 1000 10 120 
19 1000 750 3000 10 120 
20 300 250 3000 20 40 
21 300 250 3000 10 120 
22 300 750 1000 10 40 
23 1000 750 1000 20 40 
24 300 750 1000 20 40 
25 1000 250 1000 10 120 
26 300 750 1000 20 120 
27 1000 250 3000 10 120 
28 300 250 1000 10 40 
29 300 250 3000 10 40 
30 1000 750 1000 10 120 
31 1000 750 1000 10 120 
32 1000 750 3000 10 40 
T.80= Tween 80, P.90= Phospholipon 90 
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2.2.7.1 HPLC conditions 
  Chromatographic analysis was carried out using a Shimadzu® HPLC system 
consisting of a Shimadzu auto injector SIL 10A®, Shimadzu system controller SCL-
10A®, a Shimadzu SPD 10A UV® detector and a Shimadzu LC 10AS HPLC pump all 
from Shimadzu Scientific Instruments (Columbia, MD). Separations were carried out on 
a  Sphereclone® C-18 column (150mm X 4.6mm with a particle size of 5µm) from 
Phenomenex (Torrance, CA) equipped with a guard column (30 X 4.6mm) also from 
Phenomenex (Torrance, CA). The wavelength of detection was 255nm and the flow rate 
was 1.5ml/min. 
 
2.2.7.2 Preparation of Standard Solutions  
Ten milligrams of trifluoperazine hydrochloride was dissolved in 100ml 
deionized water to produce a 100μg/ml solution. The mobile phase was acetonitrile: 
monobasic ammonium phosphate (60:40), adjusted with 0.2M phosphate buffer to pH 
2.7.   
 
2.2.7.3 Linearity and Range 
Calibration curves were plotted using 1µg/ml-50µg/ml concentration range of 
trifluoperazine to determine linearity. 
 
2.2.7.4 Precision and Accuracy 
Precision and accuracy of the HPLC method were determined at 25%, 50% and 
100% of the calibration curve range to test the validity of the method at low, mid and 
 
 
 
42 
 
 
high concentrations respectively. Triplicate samples were analyzed at each level. 
Precision was calculated as percent relative standard deviation (RSD) and accuracy was 
calculated as percent relative recovery. Inter-day variation was determined by repeating 
the procedure using independent samples on three separate days.  
 
2.2.7.5 Drug Extraction 
The emulsions were extracted and analyzed for drug content using HPLC 
analysis. Trifluoperazine HCl was extracted from the nano-emulsion prior to HPLC 
analysis using the following procedure: The extract was diluted with the mobile phase 
and agitated for >1hr. The diluted solution was passed through a 0.45μm filter. The 
extracted drug from the emulsion was then analyzed for the drug content using HPLC. 
 
2.2.8 Emulsion Stability 
 
2.2.8.1 Forced degradation Study 
The optimal emulsion formulations Experiments 3 and 17 (Table 2.1) were 
prepared for the forced degradation studies. This experiment was designed determine the 
extent of emulsions degradation in terms of physical stability of the emulsions and the 
potency of the emulsions when subjected to high temperature over a period of 7 days. 
Blank emulsions were produced to compare with the drug loaded emulsions. Freshly 
prepared emulsions were stored in tightly sealed glass vials and placed in an oven at 
65
º
C. Physical stability of emulsions were monitored by determination of z-averages, zeta 
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potentials and polydispersity indices of emulsions on days 0 & 7. Potency was monitored 
by analysis of  drug content on days 0 & 7 using HPLC. 
 
 
2.2.8.2 Stress Test 
  Several stress methods can be used to predict the stability of emulsions according 
to ICH guidelines (88). These include shaking, thermal cycling and freeze-thaw cycling. 
Emulsion droplet size distributions are then assessed (89). The stress tests of the 
emulsions included centrifugation and freeze/thaw cycle of the optimal emulsion 
formulations (experiments 3 & 17). 
 
2.2.8.2.1 Centrifugation 
  Emulsions were centrifuged at 2000 X g/60min. The z-averages and zeta 
potentials of the emulsions were determined before and after centrifugation. 
 
2.2.8.2.2 Freeze/thaw cycle 
Emulsions were frozen for 24hours at -18°C and thawed at 25°C for another 24 
hours. The z-averages and zeta potential values of the emulsions were determined before 
and after the freeze/thaw cycle. 
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2.2.8.3 Accelerated stability test 
Optimal nano-emulsions of trifluoperazine: Emulsions 3 and 17 which have been 
shown to have z-averages less than 100nm were selected for stability studies at 40

C 
±2

C at 75% relative humidity (RH) ±5%RH. These emulsions were stored sealed glass 
ampoules. Emulsion characteristics such as potency, z-average and zeta potential were 
analyzed on day 0 and once a month for a period of 3 months.  
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3.0 Results and Discussion 
 
 
3.1 Preliminary Experiment Results 
The preliminary experiments were screening experiments carried out for  
selection of emulsion components. Four different oil phases: soybean oil, ethyl oleate, 
tricaprylin and tributyrin were used in order to select the most suitable oil phase for the 
emulsion. Phosphatidyl choline was obtained from six different sources: soy lecithin, 
hydrogenated egg phosphatidyl choline, phospholipon 90 G, phospholipon 90 H, lipoid 
EPC and lipoid EPC-3 were used for the preliminary formulations.   
Ethyl oleate emulsions had the lowest z-average while soybean oil emulsions had 
the highest z-average. Tributyrin emulsions had very large droplet sizes compared to the 
other formulations therefore were not further studied. Soybean oil emulsions had larger 
droplet sizes probably as a result of higher oil viscosity compared to ethyl oleate. (Figure 
3.1)  Soybean oil was selected as the oil phase despite the relatively higher emulsion 
droplet size because it has the least incidence of toxic reactions, greatest resistance to 
oxidation and widely used in research. 
Blank emulsions (without drug) and drug loaded emulsions were produced. The 
incorporation of trifluoperazine into the formulation gave emulsions with considerably 
high zeta potential and low z-average sizes. Zeta potential of soybean oil emulsion was 
increased from 2.4mV (formulation 5) without drug to 43.2mV (formulation 9) in Table 
3.1. This is because trifluoperazine confers a charge on the emulsion droplets. The 
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reduction of the z-average of emulsions can be attributed to the amphiphilic nature of 
trifluoperazine. Trifluoperazine is a cationic drug with surface active property and a 
critical micelle concentration (CMC) of 4.2 X 10
-5. 
The surfactant property should 
promote further lowering of surface tension by adsorption on the surface of oil droplets. 
Glycerin was incorporated as a component of the emulsion to confer iso-osmocity 
based on the prototype formulation of Intralipid®. This was not further explored because 
a high polydispersity indices and relatively high z-averages were obtained. A different 
technique or modification of the method may produce smaller droplet sizes. Iso-osmocity 
may also be achieved using electrolytes. 
The effect of the various sources of phosphatidyl choline was observed.  
Emulsions 11-25 were formulated using soy lecithin (Table 3.2). Concentrated emulsions 
were prepared by reducing the aqueous phase of the formulations. These emulsions 
(formulations 19-25) shown in Table 3.3 had high z-average. The increase in size may be 
due to reduced mobility as a result of the decreased aqueous phase. This possibly 
prevented collision that could yield smaller droplets. The zeta potentials of the emulsions 
were generally below 20mV thus indicating the potential instability of the emulsions. 
These emulsions had very large droplet sizes and may have exceeded the upper limit of 
detection of z-average for the Zeta sizer instrument, also the polydispersity indices at this 
point may not be reliable. Soy lecithin was not feasible in the production of nano-
emulsions because of its oily, viscous nature.  
 Lipoid EPC, Lipoid EPC-3 and Phospholipon 90G® were utilized as source of 
phosphatidyl choline in formulations 26-28 (Table 3.4).  Phospholipon 90 H was used for 
emulsions 29-31 (Table 3.5). Lipoid EPC
®
 and lipoid EPC-3
®
 are produced from egg 
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phosphatidyl choline while phospholipon 90
®
 is produced from soybean phosphatidyl 
choline (90). Phospholipon 90 was selected as the phosphatidyl choline of choice because 
emulsion with low droplet size could be produced and polydispersity index was low.  
The composition of the emulsion with the most desirable properties of low droplet 
size, low polydispersity index and high zeta potential is given in Table 3.6. 
Emulsions with low z-average are usually more stable compared with emulsions 
with larger z-average because larger droplets are more susceptible to aggregation or 
creaming. As referred to under literature review, these phenomena are undesirable and 
can lead to a more serious problem of coalescence of the emulsion droplets (91). Due to 
the very small droplet size of the nano-emulsion there is a large reduction in the 
gravitational force and Brownian motion may be sufficient for overcoming the effect of 
gravity. In addition, smaller droplet size also prevents flocculation. Weak flocculation 
(cases where the net attractive forces are relatively weak) is prevented, thus enabling the 
system to remain dispersed with no separation (92).  
  Zeta potential measurement is a useful tool in the prediction of emulsions stability. 
A zeta potential larger than 25mV is typically required to stabilize a system (93).  
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Figure 3.1 Effect different oil phases on Z-average and Polydispersity index of Emulsions 
 
 
  
Table 3.1  Preliminary Emulsions 
Form
. 
Oil (ml) Tween80(ml) HEPC 
(200mg) 
Glycerin Drug 
(mg) 
Z.ave 
(nm) 
P.I Z.P 
(mV) 
1 S.O 0.5 + - - 641.8 0.196 -12.4 
2 E.O 0.5 + - - 2198.8 0.219 -12.9 
3 S.O 0.5 + + - 374 0.84 -22.4 
4 E.O 0.5 + + - 9932 0.806
5 
-17.4 
5 S.O 1 + - - 229.7 0.034 2.4 
6 TRIC 1 + - - 221.1 0.030 2.8 
7 TRIB 1 + - - 1329.4 0.165 18.4 
8 E.O 1 + - - 91.4 0.477 2.5 
9 S.O 1 + - 40 118.5 0.54 43.2 
10 TRIC. 1 + - 40 139.2 0.3 32.5 
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Table 3. 1 Preliminary Experiments 
Formulation Tween 80 Oil Soy. Lecithin Drug (mg) Water (ml) Z.Ave (nm) P. I Z.P (mV) 
11 1ml 1ml 200mg - 10 3753.2 0.00 -64.1 
12 1ml 1ml 200mg 40 10 41.3 0.00 11.8 
13 1ml 1ml 200mg 40 10 8479.5 0.00 11.5 
14 1ml 1ml 200mg 40 10 5297.7 0.00 9.4 
15 10ml 10ml 2000mg - 100 12485.6 0.002 -28.6 
16 10ml 10ml 2000mg 400 100 10274.9 0.002 -0.1 
17 300mg 1000mg 400mg 40 40 163.2 0.002 -21.5 
18 750mg 1ml 250mg 40 40 696.4 0.002 9 
 
 
Table 3. 2 Preliminary Experiments: Concentrated Emulsions 
Formulation Tween 80 (mg) Oil (mg) P.C (mg) Drug  (mg) Water (ml) Z.ave (nm) P.I Z. P (mV) 
19 500 500 200 40 10 1347 0.002 19.7 
20 500 500 200 40 6 1825.7 0.002 22.3 
21 500 500 200 40 4 2099.7 0.002 22.8 
22 500 500 200 40 2 554.3 0.002 20.6 
23 500 500 400 40 10 825 0.002 -12.3 
24 500 500 400 40 6 3533 0.002 -7.9 
25 500 500 400 40 4 5218.4 0.002 -3.1 
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Table 3. 3 Emulsion Formulations Using 3 Different Sources of Phosphatidyl Choline 
Formulation Oil:Tween 80 ratio Phosphatidyl choline Drug (mg) Water (ml) Z.ave.(nm)) P.I Z.P (mV) 
26 1:1 Lipoid EPC 40 10 55 0.577 34.5 
27 1:1 Phospholipon 90 40 10 39.4 0.293 32.2 
28 1:1 Lipoid EP-3 40 10 153.8 0.372 32.9 
 
 
Table 3. 4 Emulsions Formulation with increasing Phospholipon 90 H® content 
Formulation T.80 (mg) P.90 (mg) Soy.oil (mg) Drug (mg) Water (ml) Z.ave.(nm)) P.I Z.P (mV) 
29 300 300 500 40 10 112.5 0.625 34.5 
30 400 400 500 40 10 52.3 0.61 32.9 
31 500 500 500 40 10 169.9 1 31.0 
 
 
Table 3. 5 Emulsion Composition (Formulation 27) 
 
Component Amount 
Soybean oil 1ml 
Phosphatidyl Choline 200mg 
Trifluoperazine 40mg 
Water 10ml 
Tween 80 1ml 
 
 
 
 
 
51 
 
 
3.2 Development of Optimal Formulations 
In these series of experiments, emulsion characteristics such as z-average, 
polydispersity index, zeta potential were optimized by changing the concentration of the 
emulsion components.   
The effect of soybean oil concentration on the mean particle size of emulsions 
was evaluated by increasing amount of soybean oil in a series of emulsions. The 
emulsions were produced in an Oil:Tween 80 weight ratio of 1:1, 2:1 and 3:1. (Table A2) 
When emulsions were prepared at 23w/w% (oil/oil+water) soybean oil concentration, the 
mean particle size was 136.2nm (Figure 3.2). The particle size fell along with the 
soybean oil concentration, at 9% w/w emulsions; the mean particle size was 34.2nm. The 
higher the oil phase ratio for an oil-in-water emulsion, the more viscous the emulsion 
since there is a greater number of oil droplets that require size reduction. This suggests 
that the oil constitutes the inner structure of the nano-emulsions, which is consistent with 
a direct o/w-type structure (94). The higher oil ratio also increases the interfacial tension 
between the aqueous phase and the oil phase, thus making it more difficult to form the 
emulsions. Polydispersity indices were generally low for all the emulsions, the highest 
being 0.46 at 23w/w%, while zeta potential of emulsions were not affected by the oil 
concentration. 
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Figure 3.2  Effect of Soybean oil concentration on Z-average of Emulsions 
 
The next step in the development of an optimal formulation was to determine the 
effect of Phospholipon 90G
®
 on the z-average of the nano-emulsions. The emulsions 
were produced at 1:1 Soybean oil:Tween 80 with increasing concentration of  
Phospholipon 90G
®
 at 0.9, 2.43,4.76,6.97 w/w% (Table A3). At high concentration of 
Phospholipon 90 G, the z-average of the emulsions were relatively high (Figure 3.3). This 
is in accordance with the HLB value of Phospholipon 90G 
®. Phospholipon 90G® was 
used as a co-surfactant because of its ability to stabilize emulsion systems. However, it 
has lipophilic properties and a lower HLB of 9, therefore, at higher concentration it will 
tend to form a water-in-oil emulsion. There is also a tendency for Phospholipon 90G
®
 to 
form emulsions that are more viscous and have a higher z-average at very high 
concentration. This is in accordance to Bancroft’s rule, which states that the type of 
emulsion is dictated by the emulsifier and that the emulsifier should be soluble in the 
continuous phase. (Bancroft, 1913) (95,96).  At high oil:surfactant ratio and high 
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Phospholipon 90G® concentration, the polydispersity indices of the emulsions also 
increased (Figure 3.4). High polydispersity index indicates that the emulsion droplet size 
are not uniform in the emulsions with large sizes. 
 
 
Figure 3.3  Effect of Phospholipon 90 on z-average of emulsions at 1:1 Soybean   
Oil:Tween 80 ratio 
 
 
 
Figure 3.4  Effect of Phospholipon 90 on Polydispersity Index of emulsions at 1:1 
Soybean Oil:Tween 80 ratio 
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The concentration of Tween 80 was increased while maintaining constant levels 
of other components of the emulsion (Table A4). It was observed that z-average of the 
emulsions reduced as the concentration of the surfactant increased (Figure 3.5). This is 
because the surfactant reduces the interfacial tension between the oil phase and the 
aqueous phase thus enhancing the formation of emulsions and reduction of z-average. 
The zeta potentials are generally about 30mV for all emulsions irrespective of Tween 80 
concentration. 
 
 
 
Figure 3.5  Effect of Tween 80 on Z. average of Emulsions 
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The drug content of emulsions was optimized by formulation of emulsions with 
increasing drug content. Drug loading of emulsions were at 0.4%, 0.6%, 0.8% and 
1.2%w/v of trifluoperazine concentration. Emulsion droplet size were  below 70nm 
indicating high concentration of drug was loaded. (Figure 3.6)  Zeta potential of 
emulsions were in the acceptable range, above 25mV. There was an increase in zeta 
potential of emulsions at a higher concentration of trifluoperazine due to increased ionic 
strength of the emulsions. This is also an indication of potential stability. (Figure 3.7) 
 
 
Figure 3.6  Effect of Optimization of Drug Content on Z.average Of Nano-emulsions 
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Figure 3.7  Effect of Optimization of Drug Content on Z. Potential Of Nano-emulsions 
 
 
 
 
3.3 Phase Diagrams 
A phase diagram indicating the region of the composition of the optimal 
formulations was plotted using JMP

 software. In order to develop the phase diagram, 
components of the emulsions were varied to determine their effect on the emulsion 
characteristics. 
From the previous experiments, representative emulsions were selected and 
shown in a phase diagram (Figure 3.8). The 3 different axes of the phase diagram 
represent the relative percentages of 3 components, the oil phase, surfactant and aqueous 
phase. The software normalizes the data so that all the components add up to 1. The 
shaded region within the phase diagram indicates the areas where optimum formulations 
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may be produced. Thirteen representative emulsions are shown in this diagram. The 
emulsions had relatively low z. average below 70nm and are also clear in appearance. 
These representative emulsions had low polydispersity indices of less than 0.5 and high 
zeta potentials, greater than 25mV. 
From the phase diagram, we could identify the trends and relationships between 
surfactants, oil phase and the aqueous phase of the emulsions. The region producing the 
optimal formulation is shown to be that of high aqueous phase ratio, which is reasonable 
for the production of oil-in-water emulsions. The emulsions included in the phase 
diagram were emulsions with oil: surfactant ratio 1:1, the aqueous phase volumes were 
10, 15 and 20mls and drug content of 40mg. A table of included emulsions is shown in 
Table A6. 
Turbid emulsions were excluded in the phase diagram in Figure 3.8. Figure 3.9 shows all 
the emulsions in the experimental design. The emulsions with higher oil surfactant ratio 
can also be seen in the diagram. These emulsions had undesirable properties such as 
increased z-average, lower zeta potentials and were very turbid. 
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Figure 3.8  Ternary Phase diagram of Soybean emulsions showing region of optimal   
formulation 
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Figure 3.9  Ternary Phase diagram of Soybean emulsions showing experimental design 
formulations 
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3.4 Viscosity of Emulsions  
The dynamic viscosity of emulsions with increasing levels of phosphatidyl 
choline was determined using the Automated Microviscometer (AMVn). These 
formulations and their compositions are shown in Table A7.  
Phospholipon 90G
®
 had a significant effect on the dynamic viscosity of the 
formulation. The dynamic viscosity increased significantly beyond 4% w/w of 
phosphatidyl choline content as shown in Figure 3.10. This is due to the nature of the 
surfactant. Phospholipon 90G
®
 is more lipophilic and imparts a higher viscosity to the 
formulation.  With increasing amount of the surfactant to oil ratio, an increase in the 
dynamic viscosity of these emulsions was observed. These data were obtained after 
dilution of emulsions at a ratio 1:50 with Millipore water. At high phospholipid levels for 
the pure undiluted emulsions as shown in Figure 3.10 the viscosity of emulsions 
increased when Phospholipon 90G
®
 content was greater than 4%. The viscosity was 
extremely high when the phospholipid content was 750mg and at high surfactant levels to 
oil ratios. 
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Figure 3.10  Effect of increasing %Phospholipon 90G
®
 on Dynamic Viscosity 
 
 
3.5 Statistical Design of Experiments 
JMP
®
 software was used to design the experiment having identified the low and 
high levels of the formulation components as shown in Table 3.7.  A completely 
randomized 2X2X2X2X2 full factorial design was used because it enables testing of the 
main effects due to factors (components) of the emulsion and determination of any 
interactions in the model, the significance of factors and elimination of bias. This yielded 
32 experiments as shown in Table 3.8. The effects of the components of the emulsion on 
attributes such as z-average, polydispersity indices, zeta potential and viscosity were 
determined.  
Analysis of variance (ANOVA) was used to determine the level of significance of 
the emulsion attributes and p-values were obtained using the ―Fit Model‖ analysis in 
Phospholipon 90 ® w/w% 
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JMP
® 
software version 4.0.  Parameter estimate values obtained from the analysis are 
given below in Table 3.9. Soybean oil showed the highest level of significance in 
determination of size based of the p-value of  < 0.0001. For polydispersity index, 
soybean oil also showed significance at p-value of  = 0.0059 and aqueous phase at  = 
0.01.For zeta potential, Tween 80 showed significance at  =0.0249 and Trifluoperazine 
at  =0.01. All emulsion components showed significance for dynamic viscosity. 
 
Table 3.7 Levels of Emulsion Factors 
Factors Level 
High Low 
X1 T80 Tween 80 1000mg 300mg 
X2 P90 Phospholipon 90 750mg 250mg 
X3 SO Soybean Oil  3000mg 1000mg  
X4 AP Millipore Water 20ml  10ml 
X5 TP Trifluoperazine 120mg 40mg  
 
 
 
 
 
The effect tests of the model were examined in order to determine the level of 
significance of the emulsion components on the Y values (z-average, polydispersity 
index, zeta potential and viscosity. The effects of interaction of any of the components, if 
present, were also determined in this statistical design. Pareto charts were plotted using 
JMP® software to show the variables and these were ordered according to their 
importance. The significance of any interactions is also shown. 
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Table 3.8  Statistical Design of Experiment Matrix 
Exp. T80 
(mg) 
P90 
(mg) 
SO 
(mg) 
AP 
(ml) 
TP 
(mg) 
Size 
(nm) 
PD Z.P 
(mV) 
Viscosity 
(mPa.S) 
1 300 750 3000 20 120 127.7 0.184 39.86 2.1604 
2 300 750 3000 10 40 157.2 0.145 44.61 8.7929 
3 1000 250 1000 20 40 57.1 0.244 22.2 1.8145 
4 300 250 1000 20 120 169.6 0.177 76.1 1.397 
5 1000 750 3000 20 120 74.09 0.211 36.46 2.9118 
6 1000 750 1000 20 120 73.47 0.271 34.34 2.6964 
7 300 750 3000 20 40 144.2 0.182 28.66 2.3457 
8 300 750 1000 10 120 91.71 0.223 32.92 5.2093 
9 300 250 1000 20 40 93.56 0.176 27.68 1.4337 
10 1000 250 3000 20 120 136.6 0.198 37.02 2.2481 
11 1000 750 1000 10 40 88.95 0.264 28.58 15.9533 
12 300 250 1000 10 40 97.23 0.201 29.85 2.1129 
13 300 250 1000 10 120 90.12 0.193 37.67 2.0335 
14 1000 250 1000 20 120 82.1 0.226 29.74 1.7702 
15 300 250 3000 20 40 179.1 0.213 31.89 1.733 
16 1000 250 3000 20 120 143.3 0.214 38.74 2.2214 
17 1000 250 1000 10 40 72.97 0.225 25.59 3.91 
18 300 250 1000 10 120 85.46 0.175 35.71 2.0271 
19 1000 750 3000 10 120 154.8 0.168 37.28 9.2643 
20 300 250 3000 20 40 190.1 0.236 39.64 1.7605 
21 300 250 3000 10 120 183.8 0.219 43.15 3.2152 
22 300 750 1000 10 40 81.92 0.213 29.64 5.1045 
23 1000 750 1000 20 40 66.9 0.269 23.94 2.8091 
24 300 750 1000 20 40 40.76 0.219 24.62 1.714 
25 1000 250 1000 10 120 37.93 0.199 14.22 3.4661 
26 300 750 1000 20 120 48.84 0.257 20.36 1.6605 
27 1000 250 3000 10 120 145.4 0.18 33.67 5.5925 
28 300 250 1000 10 40 90.33 0.187 33.63 1.9993 
29 300 250 3000 10 40 181.6 0.169 36.78 3.0946 
30 1000 750 1000 10 120 122 0.175 27.89 3.2214 
31 1000 750 1000 10 120 71.21 0.242 30.31 11.3596 
32 1000 750 3000 10 40 152 0.138 19.37 21.5565 
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3.5.1 Z-average Effects 
  Z-average effects and the level of significance of the individual factors as well as 
the interaction terms are shown in Figure 3.11. The concentration of soybean oil in the 
emulsion as shown in the pareto plot was the most significant factor in the determination 
of z-average of the emulsions. The significance of the oil phase in this statistical design 
further supports the effect observed in the phase diagrams that increasing the amount of 
soybean oil of the emulsions increased the z-average as shown previously in Figure 3.8. 
The interaction of the Phospholipon 90G
®
 and the aqueous phase are seen to be the 
second most important factor based on the pareto plot in Figure 3.11. The Pareto plot 
shows the factors of the emulsions in order of importance with respect to the z-average of 
the emulsions.  
 
3.5.2 Polydispersity Index Effects 
 The polydispersity index data and the level of significance of the individual 
factors are shown in Figure 3.12. The most significant factor was observed to be an 
interaction of Phospholipon 90G
®
 and soybean oil. Other factors shown in decreasing 
order of importance are soybean oil, aqueous phase and Tween 80. The polydispersity of 
the emulsion shows the width of distribution of emulsion size, will be influenced by all 
these factors as shown in Figure 3.12. 
 
3.5.3 Zeta Potential Effects 
  The zeta potential data and the level of significance of the individual factors are 
shown in Figure 3.13.  The most important factor having significance on the zeta 
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potential of the emulsions is shown here to be the concentration of trifluoperazine in the 
emulsion. This is supported by the nature of the drug which confers a positive surface 
charge on the emulsion droplets. All other factors and interaction terms are shown in 
decreasing other of importance in the pareto plot. 
 
3.5.4 Viscosity effects 
The most important factor in the determination of viscosity was the aqueous phase 
of the emulsion as shown in the pareto chart (Figure 3.14). Phospholipon 90G
® 
was a 
contributing factor and this confirms the previous findings of the influence of 
Phospholipon 90G
® 
on viscosity of emulsions. 
Graphs showing overlay plot of studentized residuals versus order of experiments 
were plotted for all the different Y variables. This data did not have any specific pattern 
thus indicating that there are no outliers in the data obtained. Studentized residuals did 
not indicate the presence of any outliers. 
 
 
3.5.5 Optimal Emulsions 
  From the experimental design, emulsions 3 &17 were selected as best and 
optimal for consideration in the stability studies. The acceptable formulation criteria 
were: low z-average less than 100nm, low polydispersity indices <0.5 and relatively high 
zeta potentials >25mV. 
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Table 3. 9 Parameter Estimates of Size, Polydispersity Index, Zeta Potential and Dynamic 
Viscosity obtained from JMP
® 
by ANOVA 
Size 
Term Estimate Std Error t Ratio Prob>|t| 
T80[300] 9.5947728 5.12255 1.87 0.0723 
P90[250] 8.4748422 4.953124 1.71 0.0990 
S0[1000] -35.12499 5.027934 -6.99 <.0001 
AP[10] 5.8354374 4.947362 1.18 0.2489 
TP[40] 0.3127429 5.08468 0.06 0.9514 
Polydispersity 
T80[300] -0.008195 0.005362 -1.53 0.1385 
P90[250] -0.003302 0.005185 -0.64 0.5298 
SO[1000] 0.0157765 0.005263 3.00 0.0059 
AP[10] -0.013549 0.005179 -2.62 0.0146 
TP[40] 0.0013753 0.005323 0.26 0.7981 
Zeta Potential 
T80[300] 4.1554993 1.745036 2.38 0.0249 
P90[250] 1.6340967 1.687319 0.97 0.3417 
SO[1000] -2.356583 1.712804 -1.38 0.1806 
AP[10] -0.827518 1.685356 -0.49 0.6275 
TP[40] -3.952409 1.732135 -2.28 0.0309 
Dynamic Viscosity 
T80[300] -1.696946 0.552771 -3.07 0.0050 
P90[250] -1.796257 0.534489 -3.36 0.0024 
SO[1000] -1.006527 0.542561 -1.86 0.0749 
AP[10] 2.2476529 0.533867 4.21 0.0003 
TP[40] 1.143537 0.548685 2.08 0.0471 
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SO[1000]
P90[250]*AP[10]
T80[1000]
T80[1000]*P90[250]
P90[250]
AP[10]
T80[1000]*AP[10]
P90[250]*SO[1000]
T80[1000]*SO[1000]
SO[1000]*AP[10]
P90[250]*TP[120]
AP[10]*TP[120]
T80[1000]*TP[120]
SO[1000]*TP[120]
TP[120]
Term
 -33.82046
 -13.22272
 -11.07343
 -10.72185
   8.73181
   5.78596
   5.69183
  -5.17179
   4.79023
  -4.28642
   4.00872
  -2.04046
  -1.95801
   1.09816
  -0.30166
Orthog Estimate
 
Figure 3.11  Pareto plot of Z-average Using Emulsions in the Statistical Design 
 
 
 
 
P90[250]*SO[1000]
SO[1000]
AP[10]
T80[1000]
T80[1000]*SO[1000]
T80[1000]*TP[120]
P90[250]*AP[10]
T80[1000]*AP[10]
P90[250]*TP[120]
SO[1000]*AP[10]
SO[1000]*TP[120]
P90[250]
TP[120]
AP[10]*TP[120]
Term
-0.0160713
 0.0139533
-0.0134271
 0.0083621
 0.0073507
-0.0058645
 0.0048408
-0.0047197
-0.0045366
 0.0039635
-0.0038213
-0.0034257
-0.0013266
-0.0006590
Orthog Estimate
 
Figure 3.12  Pareto Plot of Transformed Estimates of Polydispersity index Using 
Emulsions in the Statistical Design 
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TP[120]
T80[1000]
P90[250]*AP[10]
AP[10]*TP[120]
SO[1000]
P90[250]
SO[1000]*AP[10]
SO[1000]*TP[120]
P90[250]*TP[120]
AP[10]
P90[250]*SO[1000]
T80[1000]*TP[120]
T80[1000]*SO[1000]
T80[1000]*AP[10]
Term
  3.812398
 -3.371044
 -2.981904
 -2.527454
 -2.467914
  1.753727
 -1.239190
 -1.113724
  0.982851
 -0.832782
  0.681825
 -0.657069
  0.373229
  0.033710
Orthog Estimate
 
 
Figure 3.13  Pareto Plot of Transformed Estimates of Zeta potential Using Emulsions in 
the Statistical Design 
 
 
 
AP[10]
P90[250]
T80[1000]
P90[250]*AP[10]
TP[120]
T80[1000]*TP[120]
T80[1000]*AP[10]
SO[1000]
SO[1000]*TP[120]
P90[250]*TP[120]
T80[1000]*SO[1000]
AP[10]*TP[120]
SO[1000]*AP[10]
P90[250]*SO[1000]
Term
  2.231812
 -1.807897
  1.617629
 -1.195054
 -1.103028
 -0.999987
  0.957478
 -0.712697
  0.647646
  0.579539
 -0.457022
 -0.398639
 -0.313234
  0.281874
Orthog Estimate
 
Figure 3.14  Pareto Plot of Transformed Estimates of Dynamic Viscosity Using 
Emulsions in the Statistical Design 
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3.6 HPLC Method Validation  
 Pure trifluoperazine was linear in the range 1-50g/ml. The peak areas were 
analyzed and consistent and reproducible analysis was obtained. R-squared value of 
0.9993 was obtained from the calibration curve (Figure 3.15). Inter-day accuracy of 
97.97-101.3% with precision of 0.2-1.5% RSD was obtained from the calibration curve.  
Intra-day accuracy  determined by analysis of variance (ANOVA) showed that at level of 
significance (α=0.05), p-value> 0.05 and Fcal < Fcrit, indicate no significant differences 
in the results between days or different  concentration. Table A9. 
Content analysis and % recovery were determined on the basis of the calibration curve 
 
 
Figure 3.15  Calibration Curve for Trifluoperazine  
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3.7 Stability Studies of Optimal Formulations 
 
3.7.1 Forced Degradation Studies 
3.7.1.1 Z-average and zeta potential  
The optimal emulsion formulations 3 & 17 were subjected to forced degradation 
for a period of 7 days. The z-average of the emulsions increased on storage at 65
º
C for 
both sets of emulsions. Z-average distribution immediately after preparation of the 
emulsion was increased from 44.0nm to 183nm and from 43.3nm to 133.5nm for 
emulsions 3& 17 respectively after storage for 7 days. Typical z-average distribution for 
emulsion 3 on day 0 is shown in Figure 3.15 and day 7 is shown in Figure 3.16. The z-
average increased from about 36nm to over 100nm for the blank emulsions. The z-
average of the optimal emulsions and blank emulsions increased due to aggregation of 
droplets because of the high thermal energy involved when stored at 65
º
C. This relatively 
high temperature increased the thermal energy of droplets and aggregation which 
eventually led to coalescence of droplets and eventual breakdown of emulsion. 
The zeta potentials of both emulsions 3 & 17 increased after subjection to extreme 
temperature. In both cases, the zeta potential for the blank emulsion was very low since 
there are no active ingredients and therefore no charge. Increased zeta potential of 
optimal formulations can be attributed to breaking of the emulsions, thus more of the 
drug molecules are located at the interface of the emulsion droplets.  
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Table 3.10 Forced Degradation Test 
 Emulsion 3 Blank Emulsion 3 
 
Emulsion 17 Blank Emulsion 17 
 Z.Ave. 
(nm) 
(nm) 
Z.P 
(mV) 
Z.Ave. 
(nm) 
Z.P 
(mV) 
Z.Ave. 
(nm) 
Z.P 
(mV) 
Z.Ave. 
(nm) 
Z.P 
(mV) 
Day 0 44.0 14.86 36.0 2.34 43.3 16.45 37.5 1.93 
Day 7 183.3 16.2 90.5 5.05 93.1 18.58 100.7 6.03 
 
 
 
3.7.1.2 Potency 
The drug content of emulsions 3 &17 were determined by HPLC.  The emulsions 
were stored at 65

C for 7 days. Calibration curves were plotted for standards and potency 
was extrapolated from the curve. Drug content of emulsion 3 was reduced to 69.2 % after 
7 days and potency of emulsion 17 was reduced to 72% after 7 days. Chromatograms of 
emulsions 3 on day 0 showed retention time of 8.5 minutes as shown in Figure 3.17 
HPLC analysis showed emulsion degradation occurred. Figure 3.18 shows that the 
absorbance was reduced after 1 week of storage at 65

C. Blank emulsions containing no 
drug were included in the experiment to serve as control.  
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Figure 3.16  Z-average Distribution of Emulsion 3 at day 0 
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Figure 3.17 Z-average Distribution of Emulsion 3 after 1 week 
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Figure 3.18 Typical Chromatogram at Day 0 
 
A
b
so
rb
an
ce
 (
m
V
) 
 
 
 
 
74 
 
 
3.7.2 Stress test of Optimal Formulations 
 3.7.2.1 Centrifugation 
 Emulsions were centrifuged at 2000 X g/60min. Z-averages of emulsions were 
determined before and immediately after centrifugation. From the results obtained, it was 
observed that there were no significant changes in the z-average and the zeta potential of 
the emulsions before and after centrifugation on day 0 (Table 3.13). 
 
3.7.2.2 Freeze/thaw cycle 
 Emulsions were frozen immediately after preparation for 24 hours at -18°C and 
thawed at 25°C for another 24 hours. The z-average values of the emulsions were 
 
 
 
 
Figure 3.19  Typical Chromatogram of Emulsion stored at 65C  after 1 week 
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determined before and after the freeze/thaw cycle. All emulsions showed creaming after 
one freeze/thaw cycle process. A single cycle showed large increase in z-average of 
emulsion. Z-averages and the zeta potentials of emulsions increased considerably after 
the cycle.  Emulsions 3 increased from 48.8nm to 243nm in z-average and Emulsion 17 
increased from 51nm to 220.8nm. The zeta potentials of emulsions were observed to 
increase after the freeze thaw cycle. Destabilization of emulsion was greater with the 
freeze-thaw cycle than centrifugation. Majority of oil droplets were compressed together 
between the advancing ice crystals as the continuous phase of the emulsion freezes and it 
is not surprising that most of the oil droplets have coalesced (97). This is in contrast to 
centrifugation which is characterized by an insignificant change in z-average and zeta 
potential of emulsions. 
Table 3. 11 Stress Test 
 
Experiment Stress Test 
Z-average (nm) Zeta Potential (mV) 
Before After Before After 
Emulsion 3 
Centrifugation 48.89 48.99 21.1 23.8 
Freeze/Thaw 48.89 243.5 21.1 32.7 
Emulsion 17 
Centrifugation 51.56 52.33 20.5 20.8 
Freeze/Thaw 51.56 220.8 20.5 34.6 
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3.7.3 Accelerated Stability Test  
Accelerated stability test of selected Soybean emulsions of trifluoperazine was 
developed according to the International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for Human Use (ICH) guidelines. The 
guideline recommends storage at 40

C ±2

C at 75% relative humidity (RH) ±5%RH. A 6-
month study is recommended for an accelerated stability study. However, if significant 
change occurs within the first 3 months it is considered unnecessary to continue to test 
through 6 months (98). 
Emulsions 3 and 17 shown in the statistical design were reproduced in triplicates and 
used for the accelerated stability study. Emulsions were stored at 40ºC±2/ 75 RH ±5% 
RH. Drug content analysis of emulsions using HPLC, z-average and zeta potential of the 
emulsions were determined over 3 months. 
 
 
3.7.3.1 Content Analysis of Emulsions 3 and 17 
  Drug content of Emulsions 3 & 17 was determined on day 0 by HPLC after 
extraction of pure drug from emulsions by agitation for 1 hour in the mobile phase. The 
emulsions were filtered using 0.45µm filter and then analyzed by HPLC.  
Emulsions were stored in glass ampoules at 40ºC±2/75 RH ±5% RH, room. Drug 
content analyses of emulsions were determined after 1 month, 2 months and at 3 months 
(Table A10). These emulsions showed less than 75% potency after 3 months of storage .  
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Figure 3.20  HPLC Analysis of Emulsions 3 & 17 at 40ºC/ 75RH 
 
 
Emulsion breakdown can occur through physical degradation such as flocculation, 
Ostwald ripening etc. as discussed previously in the literature review and chemical 
degradation due to the instability of the drug. Factors responsible for the degradation of 
trifluoperazine were due to temperature, pH, air and light induced oxidation. The most 
likely degradation pathway for trifluoperazine is as shown in the figure below. Oxidation 
of trifluoperazine occurs through a two-step reaction involving the intermediate 
formation of a semiquinone free radical which is then oxidized to the sulfoxide. 
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Trifluoperazine 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.21 Degradation Pathway of Trifluoperazine 
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3.7.3.2 Z-average analysis and Zeta Potential of Emulsions 3 &17 after 3 
months storage at 40
º
C/75% RH  
Z-average results were determined using the Nicomp particle sizer after 1, 2 &3 
months of storage at 40ºC/75 RH. Emulsion 3 had a z-average of 45.3nm immediately 
after preparation. Z- average value for Emulsion 3  was 61.4nm at 40
º
C after 3 months. 
The z-average of Emulsion 17 also increased from 21.3nm at day 0 to over 101.7 nm 
after 3 months at 40
º
C/75RH.  
Zeta potential value for Emulsion 3 was 17.34mV on day 0, this reduced 
drastically to 3.97 mV at 40
º
C (Table 3.12).  Zeta potential of Emulsion 17 on day 0 was 
21.32mV; this decreased to 6.36mV and 3.97mV after 3 months at 40ºC/75%RH. 
 
Table 3.12  Accelerated Stability Tests showing Z. average and Zeta potential Data For  
Z-average and Zeta Potential of Emulsions 3 & 17 Stored at 40ºC and 75RH 
 
Z-average 
 (nm) 
Zeta potential 
(mV) 
Emulsion 3 17 3 17 
DAY 0 45.3 21.3 17.34 21.32 
1 MONTH 71.3 93.9 14.1 5.27 
2 MONTHS 67.3 126.5 10.82 3.63 
3 MONTHS 61.4 101.7 7.5 3.97 
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3.8 Summary 
This research study describes a novel method for the preparation and 
characterization of emulsions intended for parenteral delivery using the thin layer 
hydration method. It is a very versatile method for producing nano-emulsions.  
 Oil-in-water nano-emulsions of trifluoperazine for parenteral delivery were 
produced using soybean oil and a blend of surfactants; Tween 80 and Phospholipon 
90G
®
. This was developed with the intention to provide a system which is more stable 
and better formulated to possibly prevent adherence to PVC tubing. 
 
3.8.1 Emulsion Formulation and Characterization 
Emulsions were formulated and characterized to determine z-average, 
polydispersity, zeta potential and viscosity. The emulsion components such as soybean 
oil, Tween 80, Phospholipon 90G
®
, Millipore water and trifluoperazine were varied to 
produce an optimal formulation. The oil: surfactant ratio was a very important factor in 
the determination of the z-average of the emulsions. Phase diagrams were produced 
following the preliminary emulsions and this showed the best formulation parameter 
ranges for emulsion formulation. A 2X2X2X2X2 factorial statistical experiment was 
designed to test the significance of the emulsion components and determine the influence 
of various emulsion components on the emulsion characteristics. Pareto charts were 
plotted to evaluate the significance of the factors and the presence of interactions if any. 
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Emulsions with z. averages of less than 100 nm were obtained. The small z-
average of the emulsions suggests that emulsions will be stable. They also had 
polydispersity indices of less than 0.4. Zeta potentials were greater than 20 mV indicating 
potential stability of emulsions. Viscosity data was obtained for emulsions. Viscosity data 
can be exploited as index of emulsion stability if changes are observed in the emulsion 
viscosity with time. 
 
3.8.2 Stability and HPLC Analysis 
   Emulsions were analyzed using HPLC immediately after production to determine 
drug content. Stability tests were done at 40ºC/75 RH to determine the level of 
degradation according ICH guidelines. The emulsion droplet sizes were not significantly 
increased thus indicating that the method is useful in formation of emulsions that can 
maintain integrity without breaking or coalescing. The drug content of emulsions was 
observed to reduce on storage mainly as a result of chemical degradation of the drug. 
The success of an emulsion as a drug product is dependent on the z-average, the 
zeta potential also the characteristics of the drug in question. The chemistry of a drug 
plays a large role in the determination of the zeta potential and how quickly a drug will 
be degraded. Other components may be included in the formulation to ensure stability of 
drug for further development. This method is very useful in the initial development 
process of drugs to be formulated as emulsions. 
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5.0 Appendix 
 
 
Table A 1 Preliminary  Emulsions 
Formulation Oil phase Oil Phase Tween 80  Phosphatidyl choline Drug (mg) 
1 S.O  0.5 200mg 0 
2 E.O  0.5 200mg 0 
3 S.O  0.5 200mg 0 
4 E.O  0.5 200mg 0 
5 S.O  1 200mg 0 
6 TRIC  1 200mg 0 
7 TRIB  1 200mg 0 
8 E.O  1 200mg 0 
9 S.O  1 200mg 40 
10 TRIC.  1 200mg 40 
11 S.O 1ml 1ml 200mg) - 
12 S.O 1ml 1ml 200mg 40 
13 S.O 1ml 1ml 200mg 40 
14 S.O 1ml 1ml 200mg 40 
15 S.O 10ml 10ml 2000mg - 
16 S.O 10ml 10ml 2000mg 400 
17 S.O 300mg 1000mg 400mg 40 
18 S.O 750 1ml 250mg 40mg 
19 S.O 500mg 500mg 200mg 40mg 
20 S.O 500mg 500mg 200mg 40mg 
21 S.O 500mg 500mg 200mg 40mg 
22 S.O 500mg 500mg 200mg 40mg 
23 S.O 500mg 500mg 400mg 40mg 
24 S.O 500mg 500mg 400mg 40mg 
25 S.O 500mg 500mg 400mg 40mg 
26 S.O 1ml 1ml Lipoid EPC (250mg) 40mg 
27 S.O 1ml 1ml Phospholipon 90 
(250mg) 
40mg 
28 S.O 1ml 1ml LipoidEP-3 (250mg) 40mg 
29 S.O 500mg 300mg 300mg 40mg 
30 S.O 500mg 400mg 400mg 40mg 
31 S.O 500mg 500mg 500mg 40mg 
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Table A 2.  Effect of Increasing  Oil: Surfactant ratios on Z. average, polydispersity and 
zeta potential 
 
 
Formulation Tween 
80 
 Oil: 
Surfactant 
ratio 
Water Soy. 
oil 
P. 90 Z.Ave 
(nm) 
P.I Z.P 
(mV) 
32a 1000
mg 
1:1 10ml 1000
mg 
250mg 32.9 0.316 30.4 
32b 1000
mg 
1:1 10ml 1000
mg 
250mg 35.5 0.412 29.7 
33a 1000
mg 
2:1 10ml 2000
mg 
250mg 110.7 0.385 30.6 
33b 1000
mg 
2:1 10ml 2000
mg 
250mg 105.3 0.303 28.6 
34a 1000
mg 
3:1 10ml 3000
mg 
250mg 123.4 0.509 30.0 
34b 1000
mg 
3:1 10ml 3000
mg 
250mg 149.0 0.420 31.9 
 
 
 
 
 
 Table A 3.  Effect of phosphatidylcholine on z-average, polydispersityindex and zeta 
potential (Soybean oil: Tween 80 1:1) 
 
Form. T.80 
(mg) 
Soy. Oil 
(mg) 
 
 
 
 
 
 
(mg) 
Water 
(ml) 
P.90 
(mg) 
Z.Ave 
(nm) 
P.I Z.P 
(mV
) 
35a 1000 1000 10 750 187.1 0.405 27.1 
35b 1000 1000 10 750 184.6 0.415 37.8 
36a 1000 1000 10 500 65.0 0.418 32.7 
36b 1000 1000 10 500 81.5 0.398 26.6 
32a 1000 1000 10 250 32.9 0.316 30.4 
32b 1000 1000 10 250 35.5 0.412 29.7 
37a 1000 1000 10 100 44.1 0.340 35.9 
37b 1000 1000 10 100 44.6 0.357 31.8 
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Table A4. Effect of increasing amount of Tween 80 on Average of Emulsions 
 
 
 
Form. 
Formulation 
Tween 80 (mg) Z-average (nm) 
52a 300 97.2 
52b 300 104.7 
53a 650 67.3 
53b 650 55.4 
54a 1000 30.1 
54b 1000 29.9 
 
 
 
 
 
Table A5. Emulsion formulations varying the concentration of Trifluoperazine 
 
 
Form. T.80  
(mg) 
Soy. oil  
(mg) 
Drug  
(mg) 
Water 
 (ml) 
P. 90  
(mg) 
Z. Ave. 
(nm) 
P.I Z.P 
(mV) 
54a 1000 1000 40 10 250 30.1 0.288 29.6 
54b 1000 1000 40 10 250 29.9 0.171 24.0 
54c 1000 1000 40 10 250 38.0 0.384 33.3 
55a 1000 1000 60 10 250 28.2 0.170 28.3 
55b 1000 1000 60 10 250 63.6 0.299 26.2 
55c 1000 1000 60 10 250 30.9 0.240 31.1 
56a 1000 1000 80 10 250 64.0 0.347 28.8 
56b 1000 1000 80 10 250 29.3 0.226 31.7 
56c 1000 1000 80 10 250 64.6 0.500 33.8 
57a 1000 1000 120 10 250 43.8 0.277 31.7 
57b 1000 1000 120 10 250 30.0 0.196 30.9 
57c 1000 1000 120 10 250 32.4 0.217 36.4 
 
 
 
 
 
94 
 
 
Table A6 Select Emulsions included in the phase diagram 
 
Form. Soy. Oil 
(mg) 
T. 80 
(mg) 
P.90(mg) Water Z. Ave 
(nm) 
Z.P(mV) P.I 
32a 1000 1000 250 10000 32.9 30.4 0.316 
32b 1000 1000 250 10000 35.5 29.7 0.412 
36a 1000 1000 500 10000 65 32.7 0.418 
37a 1000 1000 100 10000 44.1 35.9 0.34 
37b 1000 1000 100 10000 44.6 31.8 0.357 
44a 1000 1000 250 20000 53.3 26.2 0.335 
44b 1000 1000 250 20000 57.5 30.8 0.37 
47a 1000 1000 100 20000 66.2 31.3 0.338 
48a 1000 1000 100 15000 49.4 31.8 0.319 
49a 1000 1000 250 15000 65 27.6 0.494 
49b 1000 1000 250 15000 50.7 26.3 0.331 
50a 1000 1000 500 15000 67.2 27.3 0.417 
50b 1000 1000 500 15000 63.9 29.6 0.421 
 
 
 
 
Table A7 Effect of Phospholipid concentration on Emulsion viscosity 
 
Formulation Surf./oil ratio  T. 80 (w/w%) P. 90 (w/w%) Viscosity 
Av. 
dynamic 
viscosity 
(mPa.S) 
 
41a 0.36 7.07 0.71 0.8795 
41b 0.36 7.07 0.71 0.8795 
34a 0.41 6.99 1.74 0.8825 
34b 0.41 6.99 1.74 0.8825 
42a 0.49 6.87 3.40 0.8826 
42b 0.49 6.87 3.40 0.8826 
43a 0.58 6.76 5.07 0.8995 
43b 0.58 6.76 5.07 0.8995 
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Table A9 Analysis of Variance HPLC 
 
 
 
 
 
 
Table A10. Drug Content Analysis Of Emulsions 3 and 17 by HPLC after 3 
Months Stability Studies 
 
40ºC 
% Potency 
Day 0 
% Potency 
3 Months 
Emulsion 3 113.5 62.62 
Emulsion 17 106.81 36.04 
 
 
 
 
 
Anova: Two-Factor Without Replication 
   
       SUMMARY Count Sum Average Variance 
  Low 3 302.62 100.8733 15.11323 
  Medium 3 300.94 100.3133 2.420133 
  High 3 299.88 99.96 0.0976 
  
       Day 1 3 299.03 99.67667 2.777433 
  Day  2 3 300.28 100.0933 0.838933 
  Day 3 3 304.13 101.3767 12.29563 
  
       
       ANOVA 
      Source of 
Variation SS df MS F P-value F crit 
Levels 1.272622 2 0.636311 0.08331 0.92162 6.944272 
Days 4.710556 2 2.355278 0.308369 0.750671 6.944272 
Error 30.55138 4 7.637844 
   
       Total 36.53456 8         
